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CHARACTERIZATION OF DRRAB COMPLEX FROM STREPTOMYCES PEUCETIUS AS
A MULTIDRUG TRANSPORTER

by

WEN LI

Under the Direction of Parjit Kaur, PhD

ABSTRACT
The soil bacterium Streptomyces peucetius produces two widely used anticancer
antibiotics doxorubicin and daunorubicin. Present within the biosynthesis gene cluster in S.
peucetius is the drrAB operon which codes for a dedicated ATP-binding cassette type transporter
for the export of these two closely related antibiotics. DrrAB system was believed to be the
single-drug transporter due to its dedicated nature; however, our study demonstrated under both
in vivo and in vitro conditions that DrrAB system can transport not only doxorubicin but also
Hoechst 33342 and ethidium bromide. Moreover, many other well-studied multi-drug resistance
proteins substrates (including verapamil, vinblastine and rifampicin) inhibit DrrAB-mediated
doxorubicin transport, indicating they are also substrates of DrrAB pump. Kinetic studies show

competitive inhibition of doxorubicin transport by Hoechst 33342 and rifampicin and noncompetitive inhibition by verapamil, suggesting the possibility of more than one drug binding
site in the DrrAB system. This is the first in-depth study of a drug resistance system from a
producer organism, and it shows that a dedicated efflux system like DrrAB contains specificity
for multiple drugs.
Our study also provides the first direct evidence for the dual role of the metalloprotease
FtsH in the biogenesis of membrane proteins. We found that FtsH is not only responsible for
proteolysis of unassembled DrrB protein but it also plays a much broader role in biogenesis of
the DrrAB complex. DrrA and DrrB proteins expressed together in a temperature sensitive ftsH
mutant strain were found to be non-functional due to their incorrect assembly. Simultaneous
expression of wild-type FtsH in trans resulted in normal doxorubicin efflux. Strikingly,
doxorubicin efflux could be restored in mutant cells irrespective of whether FtsH was expressed
simultaneously with DrrAB or expressed after these proteins had already accumulated in an
inactive conformation, thus providing crucial evidence for the ability of FtsH to refold the
misassembled proteins. Complementation experiments also showed that the catalytic ATP
binding domain of FtsH contains a chaperone-like activity, however both the catalytic and the
proteolytic domains of FtsH are required to be present and work coordinately to participate in
biogenesis of DrrAB complex in the membrane.
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1
1.1

GENERAL INTRODUCTION

Multidrug Resistance and ABC Transporters
In the chemotherapies of cancer and infectious diseases, multidrug resistance (MDR) is

seen to develop in more than 90% of the patients. This resistance can be caused by the decreased
uptake of drugs, altered cell cycle checkpoint, altered drug target or the increased efflux of drugs
by drug transporter (1). In tumor cells, the major reason for multidrug resistance is the over
efflux of anti-cancer drugs. The first and the most well-characterized multidrug transporter in
human cells is P-glycoprotein (P-gp), which belongs to the ATP-binding cassette (ABC)
superfamily. Proteins in this family share highly conserved domains and functions, including
nucleotide binding domains (NBDs) and transmembrane domains (TMDs). Members of the
ABC superfamily range from prokaryotes to eukaryotes. In eukaryotes, most ABC transporters
only carry out drug efflux, while in prokaryotes, ABC proteins include both importers and
exporters (2).
Most members of the ABC superfamily mediate the transport of highly specific
substrates, following the “lock-key” hypothesis (3); however, some transporters and are
categorized as multidrug transporters. Well-characterized multidrug transporters in eukaryotic or
prokaryotic cells include P-gp, MsbA, LmrA and Sav1866, etc. (4-7). This study focuses on the
prototype drug transporter DrrAB found in Streptomyces peucetius, a soil organism that produces
anticancer drugs doxorubicin (Dox) and daunorubicin (Dnr) (8). The DrrAB system shows
sequence, structural and functional similarities to the P-gp drug transporter of human cells (9,10).
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1.2

Characterization of P-glycoprotein
P-gp is known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-

family B member 1 (ABCB1). It was first discovered by Biedler and coworkers, who found that
Chinese Hamster cells, which are resistant to actinomycin D, are also cross-resistant to other
several antibiotics (11).
P-gp is encoded by a single polypeptide chain with 1280 amino acids and assembled as
two homologous halves in the plasma membrane (12). These two halves are not identical, but
share 43% sequence identity and 78% similarity (12). They are connected by a central linker.
Each half contains one TMD (with six transmembrane helices (TMH)) and one cytoplasmic ATP
binding domain or NBD (13). The two TMDs from each halve form a large drug transport
channel with 12 TMHs connected by loops, while the two ATP binding domains constitute the
cytosolic ATP binding pockets. The NBD contains conserved motifs shared by other proteins in
the ABC transporter family, such as Walker A (P-loop), Walker B, ABC signature, Q-loop and
switch region (H-loop) (14). These conserved motifs are involved in ATP binding and
hydrolysis, energy transduction, and the cross-talk between NBD and TMD. The NBDs of most
ABC transporters share high homology irrespective of their substrate specificities while the
sequence and structure of TMDs varies significantly (15).
P-gp is expressed in tumor cells and normal tissue cells, its main physiological function is
to protect sensitive organs, such as intestine, brain or placenta by pumping the drugs or toxic
agents into bile, urine or lumen of gastrointestinal tract (16). In tumor cells, P-gp is overexpressed thus leading to the resistance of anti-cancer drugs used for chemotherapy.
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1.3

P-glycoprotein is a multidrug transporter
P-gp can interact with a wide range of structurally unrelated chemical compounds,

including natural products, anticancer drugs, steroids, fluorescent dyes, linear and cyclic
peptides, etc. According to the type of interactions, these drugs are classified as substrates or
modulators. Substrates that are transported by P-gp through the membrane, such as
anthracyclines (doxorubicin, daunomycin), and vinca alkaloids (vincristine, vinblastine) (17). Pgp can also translocate fluorescent phospholipids such as C6-NBD-diacylglycerol (18) or lipidbased drugs. Modulators can block the function of the transporter and generate a drug
concentration gradient; some of them can also be effluxed by the transporter, such as verapamil
and cyclosporine A (19). A modulator has very significant clinical application by reversing the
multidrug resistance problem during cancer chemotherapy. A combination of anti-cancer drugs
and modulators will greatly improve the effect of cancer cells treatment (20).
1.4

Mechanism of drug transport
Gottesman and co-workers had proposed the hydrophobic vacuum cleaner model (4,17),

which now has been extended to many other MDR proteins (21).

In this model, substrate first

interacts with the lipids phase. With the energy provided by ATP hydrolysis, P-gp detects the
hydrophobic substrate from the lipid bilayer and extracts the substrates from inner leaflet to the
extracellular medium (22-26). Strong evidences to support this hypothesis include the early
studies by Victor Ling’s group, which suggested that P-glycoprotein transports Hoechst 33342 or
LDS-751 from the cytoplasmic leaflet of the plasma membrane directly to the extracellular
medium (22,27,28). LmrA, the homologue of Pgp, may also transport lipophilic substrate by a
vacuum cleaner mechanism (29).
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The complete process of drug efflux requires a series of conformational changes of the
drug transporter, which can be divided into four steps (30,31).
(1) Initial binding of substrate to the drug binding pocket;
(2) ATP binding and dimerization of two NBDs;
(3) Hydrolysis of ATP resulting in the efflux of the drugs, which causes drug binding affinity
to switch from high to low;
(4) Resetting of the transport back to the original state after the reaction cycle.
1.5

Drug binding sites on Pgp
During the last two decades, the studies of P-gp drug transporter have revealed specific

drug binding locations, the kinetic interactions of multiple drugs and the energy coupling
between ATP hydrolysis and drug efflux.
As P-gp can interact with unrelated chemical compounds, the question whether Pgp
contains one single flexible and open drug binding site or multiple drug binding sites with
different binding affinities is still not clear. The presence of multiple drug interaction sites has
been demonstrated by a number of groups. For example, in 1997, Shapiro and Ling’s group
identified two drug binding sites on P-gp. The H-site preferentially transports Hoechst 33342
and the R-site preferentially transports rhodamine 123 (32). These two sites interact in a
cooperative manner. Later, they further discovered the third drug-binding site, which has a
positively allosteric effect on the drug transport through H and R sites (33). In 2000, Richard
Callaghan found the presence of at least four distinct drug interaction sties on P-gp using
equilibrium and kinetic radioligand binding assays (34). Specific residues potentially involved
in the drug binding were subsequently identified by Loo and Clark via a combination of cysteine
scanning mutagenesis and thiol-modification techniques. The thiol-reactive compounds include
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the drug substrate dibromobimane (dBBn) (35-37) and the drug substrate analogues
methanethiosulfonate (MTS)-verapamil (38) or MTS rhodamine (39). First, single cysteine
substitution mutation of every residue in the TMDs was generated; the expression level and
function of these mutations were confirmed. The residues protected by drug substrates from
being labeled by thiol-reactive analogs were identified as potential drug binding sites. This work
showed that residues in TMHs 4-6 in TMD1and TMHs 9-12 in TMD2 of P-gp are involved in
the drug binding process.
P-gp has been proven to contain multiple drug binding sites by various techniques;
however, other studies suggest that P-gp contains a large single drug binding pocket . Loo and
Clark showed that the P-gp drug binding pocket can bind verapamil and TMEA simultaneously,
and these two drugs may occupy different regions of the shared drug-binding pocket (40). This
phenotype is also supported by low-resolution cryo-election microscopy structure of P-gp, which
present the existence of a large, 5 nm diameter, central chamber for drug binding inside of P-gp
(41). A much clearer crystal structure was not obtained until 2009 by Chang’s group. The apoP-gp structure contains an internal cavity of ~6,000 Å3 with a 30 Å separation of two NBDs (42).
This large internal cavity could fit at least two substrates simultaneously and the drug binding
pocket is mainly occupied by hydrophobic and aromatic residues (43-46).
1.6

DrrAB is a multidrug transporter
Streptomyces peucetius produces two anti-cancer drugs, Dox and Dnr, and is self-

resistant to these drugs due to the efflux action of membrane transporter DrrAB (47). DrrA and
DrrB proteins are coded by the drrAB operon present within the Dox biosynthesis gene cluster
(47). DrrA is the catalytic subunit (36 kDa). It belongs to the ABC family of proteins and binds
ATP in a Dox-dependent manner (48). DrrB is an integral membrane protein (30 kDa) with
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eight transmembrane α-helices and belongs to the ABC-2 subfamily (3). Two subunits each of
DrrA and DrrB interact together to form a functional tetrameric complex (49). Both DrrAB and
P-gp belong to the ABC (ATP-binding cassette) superfamily of proteins. The DrrAB system
belongs to the Class III, DRA family, and DRR subfamily of ABC proteins (50). The NBD of
DrrA shares 29% identity and 47% similarity to NBD1 and NBD2 of Pgp (48). Thus the
bacterial DrrAB system could serve as a prototype model system for understanding the function
and evolution of multidrug transporters in general.
Due to it dedicated nature, the DrrAB system was previously believed to form a singledrug-transporter. However, in our recent studies, it was shown that DrrAB is a multidrug
transporter that can carry out efflux of at least 3 different drugs: Dox, Hoechst 33342 and
ethidium bromide (8). Inhibition studies also suggest that DrrAB can interact with a number of
other well-characterized MDR substrates, such as verapamil, rifampicin and colchicine. The
interactions between two different drugs in DrrAB were also studied by kinetics analysis, which
revealed competitive inhibition of Dox efflux by Hoechst 33342 and rifampicin but noncompetitive inhibition of Dox efflux by verapamil. These findings indicate that DrrAB is a
multidrug transporter with at least two drug binding sites. This work also highlights overlaps of
the substrate specificity of the DrrAB system and Pgp as well as other bacterial MDR systems
and points to a common mechanism, and perhaps origin, for most MDR proteins.
1.7

Quality control of MDR proteins in membranes
One of the major causes of MDR is the over-expression of the drug transporters, which

results in efflux of anti-cancer drugs out of the cancer cells. Our previous studies have indicated
that DrrA and DrrB proteins need to co-assemble in the membrane to maintain the normal
function of the DrrAB complex (51). In the absence of DrrA, the expression of DrrB is
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undetectable due to its proteolysis by FtsH on the membrane. FtsH, also defined as HflB, is an
inner membrane-embedded, ATP and Zn2+-dependent metalloprotease (52). It has been shown
to play a role in quality control of soluble proteins, such as σ32, as well as membrane proteins
including SecY and YccA, etc. (53-55). FtsH protein consists of two domains: the N-terminal
AAA domain which carries out hydrolysis of ATP, and the C-terminal proteolytic domain (52).
The degradation process of FtsH is triggered by the hydrolysis of ATP and conformational
changes of the hexameric ring structure of FtsH (52). Once the peptide tail is bound by FtsH, the
peptide can be unfolded to an open structure, extracted from the membrane lipid bilayer and
translocated through the central pore into the protease chamber for further digestion (56). As
FtsH has relatively low unfolding activity, it preferentially degrades proteins with natural
structure or low thermostabilities (57).
In our studies, we have demonstrated that FtsH plays dual roles in the quality control of
the DrrAB complex; it is not only involved in proteolysis of the unassembled DrrB protein, but
also facilitates assembly of the DrrAB complex (58). We showed that the DrrAB complex is
improperly assembled in an FtsH-deficient cell and loses its drug efflux function. However,
when FtsH is co-expressed in trans in FtsH-deficient cells, the function of the DrrAB complex is
fully restored. Interestingly, the Dox efflux activity could be restored in FtsH-deficient cells
irrespective of whether FtsH was expressed simultaneously with DrrAB or expressed after these
proteins had already accumulated in a misfolded conformation. To facilitate this assembly
function, both the AAA domain and proteolytic domain need to be present and work
coordinately to refold the misfolded DrrAB into correct conformation.
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2 DUAL ROLE OF THE METALLOPROTEASE FTSH IN BIOGENESIS OF THE
DRRAB DRUG TRANSPORTER
2.1

Introduction
Membrane proteins play essential roles in cell physiology. They carry out import of

nutrients, export of toxins, antibiotics and drugs, and play important roles in energy and signal
transduction. Improper assembly of membrane proteins is known to result in various diseases.
However, because of the complexity of the assembly process and the diverse array of factors
involved, understanding mechanisms of membrane protein assembly poses a serious challenge.
The bacterial DrrAB (doxorubicin resistance proteins A and B) system is an attractive model for
studying assembly of ABC (ATP-Binding Cassette) transporters. In this system, the catalytic
function (DrrA) and the transport function (DrrB) are present on separate subunits (59), which
together form a tetrameric complex in the membrane (60) and carry out ATP-dependent efflux of
the anti-cancer drugs doxorubicin (Dox) and daunorubicin (61). Previous studies from this lab
suggested that for proper function of the DrrAB complex the DrrA and DrrB proteins may be
required to co-assemble (51). It was also shown that interaction between DrrA and DrrB is
essential for stable maintenance of DrrB in the membrane so that the expression of DrrB is
undetectable in the absence of a simultaneous expression of DrrA (60). Co-expression of DrrA
in cis or trans restores the wild-type levels of DrrB expression, therefore suggesting that DrrA
protects DrrB from proteolysis by a cellular protease. The nature of the protease and whether it
plays a specific role in quality control and biogenesis of the DrrAB complex has so far remained
uncharacterized. In this study, we examine the role of FtsH (filament temperature-sensitive
protein H) in this process.
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FtsH is a zinc-dependent metalloprotease which belongs to the AAA (ATPases
Associated with Diverse Cellular Activities) family of proteins. Along with other proteases,
such as ClpAP, ClpXP, HsIUV, and Lon, these proteins form the large AAA+ superfamily of
proteins, members of which share a similar AAA-ATPase domain (62). FtsH is evolutionarily
conserved with more than 40% sequence identity observed between bacterial, yeast and human
homologs (63). E. coli FtsH is the best studied of all known members, and it has been shown to
be the only growth-essential protease in E. coli. Yeast cells lacking the three FtsH orthologs
(two m-AAA and one i-AAA) were also found to be non-viable, demonstrating the essential
function of this enzyme in eukaryotic cells (63,64). FtsH is unique in being embedded in the cell
membrane in E. coli, and in the mitochondrial inner membrane in eukaryotes (65), where it
forms homohexameric ring-like structures. The major role of FtsH is believed to be in the
quality control of specific membrane proteins, such as degradation of the unassembled SecY and
subunit ‘a’ of F0 sector of the ATP synthase, in addition to modulating levels of some soluble
regulatory proteins (65-67).
FtsH contains two transmembrane helices at the N terminus, followed by a cytoplasmic
domain containing the catalytic AAA domain in the middle and the proteolytic domain at the C
terminus. The AAA domain (residues 144-398) consists of the conserved Walker A, Walker B
and SRH (second region of homology) motifs, which are essential for ATP binding and
hydrolysis (65).

The proteolytic domain contains the conserved Zn2+ binding motif

H417EXXH421, the third Zn2+-ligand residue E479, and the coiled-coil leucine-zipper sequence
(65). FtsH carries out proteolysis of polypeptides in an ATP and Zn2+-dependent manner, while
other AAA+ proteases, such as Lon and ClpA/P, are serine peptidases (68).

To initiate

proteolysis of a membrane protein, the putative polypeptide binding site in the catalytic AAA
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domain of FtsH is believed to capture the cytoplasmic tail (either at the N or the C terminus) of
the membrane substrate, followed by dislocation and processive unfolding of the protein to an
open structure (65). Therefore, both the catalytic AAA domain and the proteolytic domain are
required for proteolysis.
Although the major function of the AAA+ proteases is in proteolysis, they also exhibit
chaperone-like activities, which allow them to monitor the folding status of a protein, promote
disassembly or unfolding (69), and specifically degrade non-native proteins (70). For a long
time, it has been speculated that the AAA+ proteases may also have the ability to refold their
substrate proteins (71), which remains an open question till date (72). FtsH was originally
identified by Ito and co-workers in a screen to isolate factors which may assist in membrane
protein assembly (73). They used SecY-PhoA fusion to screen for stop-transfer defect (Std)
mutations, and found that such a mutation lies in the ftsH gene. Depletion of FtsH also resulted
in significant export defects of β-lactamase and OmpA in E. coli in addition to causing a strong
Std phenotype. Together, these studies indicated that FtsH may be involved in protein assembly
into and through the membrane and may play a role in determining orientation of membrane
proteins (73). In another study, FtsH orthologs Yta10 and Yta12 in yeast mitochondria were
shown to be required for the formation of a 48 kDa assembly intermediate of the F0 subunit 9
(74).

Finally, in vitro studies showed that the purified AAA domain of Yme1, a yeast

mitochondrial homolog of FtsH, suppresses aggregation of a model polypeptide (75). Despite
these observations, however, no direct evidence for the role of FtsH or its homologs in functional
assembly of membrane proteins has been obtained so far.
In this study, we provide the first direct evidence that FtsH is a dual function enzyme
containing both the protease and assembly functions. We show that not only is FtsH responsible
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for removal of the unassembled DrrB but that it is actually able to refold previously
misassembled DrrAB proteins and restore Dox efflux function of the complex. Our results also
show that while the AAA domain of FtsH provides recognition and specificity for binding of the
substrate, both ATP hydrolysis and the proteolytic functions of FtsH are used concurrently for
refolding of DrrAB and restoration of function. Our studies, therefore, not only shed light on the
mechanism of assembly of the DrrAB complex but also further elucidate the function of the FtsH
protease.
2.2

Materials and Methods

Strains and plasmids – The E. coli strains and plasmids are described in Table 1.
Media and growth conditions – E. coli cells were normally grown in LB medium at 30°C or 37
°C, unless indicated otherwise. Chloramphenicol, kanamycin, or ampicillin was added to a final
concentration of 20, 30 or 100 µg/ml, respectively, where indicated. E. coli cells used for the
Dox efflux assay were grown in TEA medium (61).
Site-directed mutagenesis of ftsH – Site-directed mutagenesis of the ftsH gene was carried out
by a Strategene QuickChange Multisite-directed mutagenesis kit (La Jolla, CA). Using
pUC18/ftsH plasmid as the template, Lys198, located in the conserved Walker A motif of the
AAA domain, was changed to aspargine. The resulting plasmid was named pUCftsH(K198N).
Another mutant, named ftsH(HEH), was obtained by substituting His417Glu418His421 in the
conserved HEAGH motif present in the proteolytic domain to Ala417Gln418Ala421. The primers
for both substitutions are shown in Table S1.
Subcloning of the AAA domain of ftsH into pUC18 vector – To completely remove the
proteolytic domain, a fragment of ftsH corresponding to the first 1194 base pairs was PCRamplified and ligated into the pUC18 vector using the EcoRI and HindIII restriction enzymes
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resulting in pUC18(AAA). This construct is referred to as ftsH(AAA) in this article. The primers
are shown in Table S1.
Subcloning of ftsH and the groESL genes – Wild-type ftsH, ftsH(K198N), ftsH(HEH) and
ftsH(AAA) genes were subcloned into pET28a vector using SnaBI and HindIII restriction
enzymes. The resulting plasmids were named pETftsH, pETftsH(K198N), pETftsH(HEH) and
pETftsH(AAA), respectively. The groES/L genes were subcloned from pKY326 (76) into
pUC18 vector using EcoRI and SmaI restriction enzymes resulting in pUCgroESL
Cloning of ftsH into the pBAD vector – Using pBAD/HisA (Invitrogen) as a template, a 3.9kb
fragment between NcoI and HindIII sites was amplified. The NcoI site was substituted with the
XhoI site in the primers used for amplification (Table S1). This resulted in deletion of the
multiple cloning sites and the polyhistidine region. The ftsH gene was amplifed from pUCftsH
using primers containing XhoI and HindIII sites and ligated to the above fragment.
Growth and Protein expression – E. coli TG1, AR796, AR797, E. coli SG1110, and E. coli
SG1126 cells containing the indicated plasmids were grown at 30 °C or 37 °C to mid-log phase
(A600nm=0.6). The proteins were induced by addition of 0.1 or 0.25 mM IPTG, and the
incubation was continued at 30 °C, 37 °C, or 42 °C for 3 h. The cells were spun down,
resuspended in 5 ml lysis buffer (2 mM Tris-Cl, pH 7.5, 20% glycerol, 2mM EDTA, 1 mM
DTT) and lysed by a single passage through a French pressure cell at 20,000 p.s.i. After
centrifugation at 10,000 X g for 15 min, the pellet represented the inclusion body fraction. The
supernatant was centrifuged at 100,000 X g for 1 h to separate the supernatant (cytosolic
fraction) and the pellet (membrane fraction). The membrane, cytosol and the inclusion body
fractions were analyzed by 12% SDS-PAGE, followed by Western-blot analysis using anti-DrrA
or anti-DrrB antibodies (60).
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Purification of the FtsH protein – FtsH protein was purified according to published protocols
(66) with modifications. E. coli HMS174(DE3) cells containing the pETftsH plasmid or its
variants were inoculated in 1liter LB medium supplemented with 30 µg/ml kanamycin at 37 °C.
The cells were grown to mid-log phase and induced with 0.25 mM IPTG at 20 °C overnight.
The membrane fraction was prepared as described earlier (60). 5 mg of the membrane fraction
was solubilized with 5 ml solubilization buffer (50 mM Tris-Cl, pH7.5, 500 mM KCl, 0.5 %
(w/v) Nonidet P-40, 15% (w/v) Glycerol, 2.9 mM 2-mercaptoethanol). The solubilized protein
was purified using Ni2+ -NTA-agarose column and eluted with a gradient of 50 to 500 mM
imidazole. Fractions containing FtsH were collected and dialyzed against 2 liters of the dialysis
buffer (10 mM Tris-Cl, pH7.5, 15% (w/v) glycerol, 50 mM KCl, 0.5% (w/v) Nonidet P-40, 5mM
MgCl2, 1 mM dithiothreitol) for 12 hours. The protein was stored at -80 °C until used.
ATPase activity assay – The ATPase activity of FtsH was detected by the malachite greenammonium molybdate colorimetric assay (66).
In vivo FtsH Proteolytic assay - Membrane-bound DrrAB proteins were used as a substrate to
determine the proteolytic activity of FtsH.

pBAD vector or the pBADftsH plasmid was

transformed into AR797 cells containing pDX101 (pSU2718drrAB). The cells were grown in
LB medium to mid-log phase and the DrrAB proteins were induced with 0.25 mM IPTG at 42
°C for 1 h. To terminate the synthesis of DrrAB, 1000 µg/ml chloramphenicol was added to the
cell culture and incubated at 42 °C for 30 min. The cells were washed extensively to remove
chloramphenicol and IPTG. After resuspending the cells in fresh medium, synthesis of FtsH
from the pBADftsH plasmid was induced by addition of 0.2% arabinose at 42 °C. An aliquot of
cell culture was taken out at 0, 30, 60, 90, 120 and 180 min. Membrane fractions were prepared
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as described above, and 20 µg total membrane protein was loaded onto 12% SDS-PAGE,
followed by Western-blot analysis using anti-DrrA, anti-DrrB or anti-FtsH antibodies.
In vitro FtsH Proteolytic assay - α-Casein was used as a substrate in vitro to demonstrate the
proteolytic activity of purified FtsH and the FtsH(HEH) protein (77). 40 µg of α-casein (Sigma
Aldrich) was mixed with 40 µg purified FtsH or FtsH (HEH) in 150 µl protease buffer (50 mM
Tris-Cl, pH8.0, 20 mM KCl, 5 mM MgCl2, 12.5 µM Zn(OAc)2, 0.5 % (w/v) NP-40, 10 % (w/v)
glycerol, 1 mM dithiothreitol) at 42 °C. The reaction was initiated by adding 8 mM ATP, and an
aliquot (20 µl) of the sample was taken out at the indicated time points. The reaction was
terminated by adding 7 µl of 4×SDS sample buffer. The samples were analyzed by 12% SDSPAGE, followed by Coomassie Brilliant blue staining.
Whole cell Dox efflux assay – The whole cell Dox efflux assay was carried out according to the
protocol published previously (61). The fluorescence spectra were recorded on an Alphascan-2
spectrofluorometer (Photon Technology International, London, Ontario, Canada). The slope of
the Dox efflux curve of the positive control (the first sample) in each panel was designated as
1.0. The efficiency of Dox efflux of each sample within one panel was calculated by dividing
the slope of the efflux curve by the slope of sample 1. The average data obtained from three
independent experiments were plotted in the histograms.

2.3

Results

FtsH is responsible for the proteolysis of unassembled DrrB – Previous studies from this
laboratory showed that DrrB is undetectable in wild-type E. coli membranes in the absence of
simultaneous expression of DrrA ((60), Fig 1A, lane 2), however stable expression of DrrB is
seen when both DrrA and DrrB are expressed together (lane 1). These results suggest that DrrB
is completely degraded when not complexed with DrrA. Review of recent literature suggested
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that proteins of the AAA+ family, especially FtsH, may be involved in the quality control of
membrane proteins (70). To determine if this is true for DrrB, three proteases, including Lon,
ClpA/ClpP and FtsH, were investigated. If any of these proteases is responsible for degradation
of unassembled DrrB, stable expression of DrrB will be observed in cells deficient in that
protease as compared to the wild-type cells. The FtsH-deficient E. coli AR797 strain (Table 1)
used in this study contains a temperature sensitive mutation in the ftsH gene, therefore it was
grown at 30 °C but the temperature was switched to 42 °C to inactivate FtsH. The Lon (SG1110) and the ClpA- (SG1126) cells were grown normally at 30 °C or 37 °C. The isogenic
E. coli AR796 parent strain was used as a control. Of the 3 protease-deficient strains tested, only
the FtsH-deficient E. coli cells showed stable expression of DrrB in the absence of DrrA (Fig.
1B, lanes 1-3) (Fig. 1C, lane 2), while the Lon- and the ClpA- cells showed no effect on the
stability of DrrB (Fig. 1C, lanes 3-4). Since DrrB was not seen in AR796 (wild-type) cells at
either 30 °C or 42 °C (Fig. 1B, lanes 1 and 2), but it was stably expressed in the 797 (FtsHts)
cells at 42 °C (lane 3), these results show that FtsH degrades unassembled DrrB. In contrast to
the expression of DrrB alone, when both DrrA and DrrB were expressed together in wild-type
796 cells at 30 °C or 42 °C, stable expression of DrrB was seen (Fig. 1B, lanes 4 and 5),
confirming that DrrA protects DrrB against FtsH proteolysis. Note that the amount of DrrA and
DrrB in the wild-type cells was less at 42 °C as compared to at 30 °C (Fig. 1B, lanes 4-5),
suggesting that the DrrAB complex acquires a more open conformation at higher temperature
resulting in partial proteolysis by endogenous FtsH. Protection of DrrB from FtsH proteolysis by
DrrA was also seen in the ClpA- and Lon- backgrounds (Fig. 1C, lanes 5-6). Together, the data
in Fig. 1 show that FtsH plays an important role in quality control of the DrrB protein when
DrrA is absent. To rule out the possibility that DrrA or DrrB may aggregate when their
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expression is induced at 42 °C, the membrane, cytosol, and inclusion body fractions were
prepared from both wild type and FtsHts cells and analyzed by Western blotting using anti-DrrA
and anti-DrrB antibodies. The data in Fig. 2 show that although some DrrB protein is present in
the inclusion body fraction in both wild type (lower panel, lane 3) and the FtsHts cells (lane 9) at
30 °C, the induction of either strain at 42 °C did not result in any increase in the amount of
inclusion body formation (lower panel, lanes 6 and 12). Moreover, no aggregated DrrAB
proteins were seen in the stacking region of the gel in any of the fractions of wild type or FtsHts
cells, indicating absence of any significant aggregation under the conditions used in these
experiments. Note that the anti-DrrB antibody is an anti-peptide antibody, therefore it shows
some cross-reactivity with epitopes in some other E. coli proteins, as explained in a previous
publication (1).
Expression of DrrB alone or DrrAB together in FtsH-deficient cells results in growth
inhibition- The growth analysis of the wild type and FtsHts cells expressing DrrB or DrrAB at
30 °C or 42 °C was carried out (Figs. 3A and 3B). The relative growth of various strains at the
four hour time point was plotted in a histogram (Fig. 3C).

The data in Fig. 3A show that the

growth of mutant FtsHts cells is compromised at 42 °C (Fig. 3A; 797, open diamonds; Fig. 3C,
Column 4) as compared to the growth of wild-type cells under similar conditions (Figs. 3A, 796,
lines; Fig. 3C, Column 2). This result is not surprising due to the essential nature of E. coli FtsH.
Interestingly, the expression of DrrB alone in FtsHts cells at 42 °C further inhibited the growth of
these cells (Fig. 3A, compare 797, open diamonds with 797/B, filled triangles; Fig. 3C, Column
7). However, growth inhibition was not seen when DrrB was expressed in wild-type cells at 42
°C (compare 796, lines with 796/B, open rectangles; Fig. 3C, column 6).

Since DrrB

accumulates in FtsHts cells but is proteolysed in wild-type cells (Fig. 1B), it allows us to
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conclude that the growth defect seen in mutant cells is caused by the accumulation of
unassembled DrrB protein. Surprisingly, however, growth inhibition was also seen in the FtsH ts
cells expressing DrrA and DrrB together at 42 °C (Fig. 3B, 797/AB, filled triangles; Fig. 3C,
Column 7). This effect was unexpected because DrrA and DrrB can be expressed together in the
wild-type cells at 42 °C without any negative effect on their growth (Fig. 3B, 796/AB, open
rectangles; Fig. 3C, Column 6). These data indicate that the DrrAB proteins expressed in FtsHts
cells at 42 °C may be misfolded, and the accumulation of misfolded membrane proteins results
in growth inhibition. It was also observed that if the FtsHts cells initially induced at 42 °C were
shifted down to 30 °C, the cell growth resumed, albeit slowly. After 43 hours of temperature
shift-down, the final growth was about half as compared to the cells induced and maintained at
30 °C (data not shown), indicating that the growth inhibition of these cells is quite severe. In
summary, the data in Fig. 3 suggest that FtsH is not only responsible for removing unassembled
DrrB (in the absence of DrrA) but it may also be critical for proper assembly of the DrrAB
complex in the membrane.
The growth defect of the FtsHts cells expressing DrrB or DrrAB at 42 °C could be
rescued by overexpression of FtsH in trans (Figs. 3A-B, open triangles; Fig. 3C, Column 8),
indicating that the absence of functional FtsH was solely responsible for this defect. The growth
defect in each case was also suppressed by overexpression of the chaperone GroESL (Figs. 3AB, filled circles; Fig. 3C, Column 9) but not to the same extent as seen with FtsH. Western blot
analysis of the membrane fractions (prepared from the four hour cultures of samples # 6-9 in
Figs. 3A-B) showed that while FtsH overexpression resulted in significant proteolysis of DrrAB
(Fig. 3D, lanes 3 and 7), overexpression of GroESL did not (lanes 4 and 8). This might imply
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that FtsH restores growth by simply removing misfolded DrrAB proteins, while GroESL is able
to alter their conformation, thus alleviating growth inhibition.
FtsH preferentially proteolyzes misfolded DrrAB - To determine if FtsH discriminates
between properly assembled and misfolded DrrAB, the effect of overexpression of FtsH
proteolysis was compared in wild type or FtsHts cells at 30 °C or 42 °C.

Interestingly,

overexpression of FtsH in either wild type (Figs. 4A-B, compare lanes 1 and 3) or FtsHts cells
(lanes 2 and 4) produced no significant proteolysis of DrrA and DrrB expressed at 30 °C,
showing that FtsH does not proteolyze properly assembled DrrAB. However, when the DrrAB
proteins were expressed in wild-type cells at 42 °C, simultaneous overexpression of FtsH
resulted in significant proteolysis (Figs. 4A-B, compare lanes 3 and 7). These data suggest that
the DrrAB proteins must acquire a partially unfolded conformation at a higher temperature (as
also seen in Fig. 1B), thus making them more susceptible to proteolysis by over-expressed FtsH.
As expected, overexpression of FtsH in FtsHts cells also showed significant proteolysis of DrrAB
expressed at 42 °C (Figs. 4A-B, lanes 4 and 8). This is consistent with the data in Fig. 3, which
suggested that the DrrAB proteins expressed at 42 °C in FtsHts cells are misfolded. (Please note
that the conformation of the DrrAB proteins in wild-type cells at 42 °C is completely different
from the DrrAB expressed in mutant FtsHts cells at 42 °C even though they are both sensitive to
overexpressed FtsH.

In a later experiment in Fig. 8, it is shown that the DrrAB proteins

expressed in wild type cells at 42 °C retain normal function, while the DrrAB expressed in FtsH ts
cells are inactive due to their misfolding)
The rate of proteolysis of misfolded DrrAB by FtsH was analyzed in a separate timecourse experiment. The misfolded DrrAB proteins were first allowed to accumulate in the
membranes of FtsHts cells by induction with IPTG for 1 hour at 42 °C. Chloramphenicol was
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added to stop further synthesis, as described under Methods. The synthesis of FtsH from
pBADftsH was induced by addition of arabinose, and the proteolysis of DrrA and DrrB by FtsH
was determined by Western blot analysis. The data in Figs. 4C and 4D (filled circles) show that
synthesis of FtsH (Fig. 4E, lower panel) resulted in increasing proteolysis of misfolded DrrA and
DrrB from the membrane. At 120 minutes after addition of arabinose, about 75-80% of DrrA
and DrrB were removed from the membrane. These observations are in agreement with the
dislocation model proposed previously for the activity of FtsH (65). No significant proteolysis
of DrrAB was seen in the absence of FtsH synthesis (Figs. 4C and 4D, filled rectangles).
The AAA domain of FtsH contains a chaperone-like activity, but it is not sufficient by itself
to restore the Dox efflux function - The growth experiment in Fig. 3B suggested that FtsH may
be critical for the assembly of the DrrAB complex. Further support for this idea was obtained by
comparing the rate of assembly of the DrrAB complex in wild type and FtsHts cells. The data in
Fig. 5 show that the assembly of DrrA and DrrB in the membrane of FtsH ts cells is significantly
compromised already at 30 °C as compared to in the wild type cells. A significant difference in
the amounts of DrrAB in the membrane of wild type and mutant cells was seen at all time points
tested (Fig. 5, compare lanes 1-3 with 7-9). However, this difference is most evident at the early
time points, which suggests that the rate of assembly of DrrAB is affected by FtsH. This is most
likely due to the partial defect of FtsH function in FtsHts cells already at 30 °C, leading to the
low efficiency of the DrrAB complex formation.
To determine if the ability to promote assembly of DrrAB resides in the AAA domain of
FtsH, variants containing mutations in the Walker A motif of the AAA domain (K198N
mutation) or the conserved amino acids in the proteolytic domain (the HEH mutation and the
AAA subclone are described under Methods) were created. The K198N allele contained a
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defective AAA domain, while the HEH mutant and the AAA subclone contained an intact AAA
domain. As expected, the K198N mutation resulted in a significantly reduced ATPase activity,
however the HEH mutant and the AAA subclone were unaffected (Table 2). The in vitro
proteolytic activity assay showed that while the wild-type FtsH completely proteolyzed α-casein
in one hour, no significant reduction in the α-casein level was seen with the HEH mutant even
after two hours of incubation (Fig. 6).

These analyses confirmed that the AAA and the

proteolytic domain mutants behave as expected. Therefore, they were used in two different
complementation experiments (described below) to determine if the AAA domain by itself is
sufficient for promoting assembly of the DrrAB complex.
The expression of the DrrAB proteins in FtsHts cells was previously shown to result in
severe growth inhibition (Fig. 3B, filled triangles). This inhibition was reversed by simultaneous
expression of FtsH (Fig. 3B, open triangles). In the next experiment, we asked whether coexpression of the HEH allele or the AAA subclone can rescue FtsHts cells from the growth
inhibition resulting from DrrAB expression. The data in Fig. 7 show that the simultaneous
expression of either the HEH mutant (Fig. 7A, open circles) or the AAA subclone (Fig. 7A, filled
triangles) with DrrAB can complement the growth defect of FtsHts cells, indicating that the AAA
domain of FtsH indeed contains a chaperone-like activity.

Interestingly, the HEH mutant

showed much better complementation of the growth defect as compared to the AAA subclone,
perhaps due to a more native conformation of the full-length HEH protein as compared to the
AAA subclone. The K198N mutation, on the other hand, showed no growth complementation
effect (Fig. 7A, open triangles), showing that the ATPase activity associated with the AAA
domain is important for the chaperone function of FtsH. Western blot analysis showed that the
DrrAB complex is membrane-associated in the FtsH(HEH), FtsH(AAA), and FtsH (K198N)-
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containing strains (Figs. 7B and 7C, lanes 5-7), and the amounts of DrrA and DrrB in these cells
were comparable to the levels in their absence (lane 3). Therefore the restoration of growth by
the HEH and AAA clones must result from a change in conformation of the DrrAB proteins
brought about by the functional AAA domain present in these two clones. Whether the HEH and
AAA variants of FtsH can also restore function of the DrrAB complex is addressed in the next
experiment.
We previously showed that the wild-type DrrA and DrrB proteins together carry out
ATP-dependent efflux of the anticancer drug doxorubicin (61). Here, we investigated whether
co-expression of the AAA subclone or the HEH allele can restore the Dox efflux function of the
misassembled DrrAB proteins expressed in FtsHts cells at 42 °C (Fig. 8). The data in Fig 8A
indicate that the rate of DrrAB-mediated Dox efflux at 30 °C in the wild-type 796 and FtsHts 797
cells is comparable (Columns 1 and 3).

Induction of wild-type cells at 42 °C showed only a

slight reduction in Dox efflux (Column 2), which is likely due to the destabilization effect
produced by high temperature on DrrAB, as seen earlier in Figs. 1 and 4. By contrast, the FtsH ts
cells induced at 42 °C showed very little or no DrrAB-mediated Dox efflux (Fig. 8A, column 4),
which was comparable to the efflux seen with control cells containing empty vector (Fig. 8A,
Columns 5 and 6). These data confirm that the DrrAB proteins are misfolded in the absence of
functional FtsH. Simultaneous overexpression of the FtsH variants, K198N, HEH or the AAA
subclone, in FtsHts cells did not restore function of misassembled DrrAB (Fig. 8B, columns 4-6),
even though restoration of growth by HEH and the AAA subclone was earlier seen in Fig. 7A.
Similarly, overexpression of GroESL also did not complement the DrrAB-mediated Dox efflux
in FtsHts cells (Fig. 8B, column 7). One possible explanation for these data could be that even
though the AAA domain of FtsH (or GroESL) is able to alter the conformation of the DrrAB
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proteins and relieve growth inhibition, it is not sufficient by itself to restore proper conformation
required for full function of the complex.
Wild-type FtsH can refold previously misassembled DrrAB and restore function Surprisingly, co-expression of wild-type FtsH restored the Dox efflux function of the
misassembled proteins expressed in FtsHts cells at 42 °C resulting in a significant recovery
(about 45%) of Dox efflux by the DrrAB complex (Fig. 8B; compare columns 2 and 3). Since
this could only have resulted if FtsH expressed in trans facilitated assembly of the complex,
these results imply that the AAA and the proteolytic domains of FtsH must work hand-in-hand to
bring about functional assembly of the DrrAB complex. In this experiment, however, FtsH and
the DrrAB proteins were expressed simultaneously by IPTG induction, therefore it was not
possible to determine if FtsH assists only the newly synthesized DrrAB to achieve proper
conformation, or if it can also bring about refolding of the DrrAB proteins that have already been
misfolded.
Therefore, in the next experiment, DrrAB and wild-type FtsH were expressed in FtsHts
cells in a sequential manner.

The ftsH gene subcloned under the control of the araBAD

promoter was induced by arabinose, while the drrAB genes remained under the control of the lac
promoter induced by IPTG. The FtsHts cells containing both the plasmids (797/AB/pBADftsH)
were grown at 30 °C to mid-log phase. The DrrAB proteins were first induced with IPTG at 42
°C for 1 hour (this condition inactivates FtsH and renders DrrAB inactive as seen in Figs. 8A and
8B). The cells were then washed several times to remove extracellular IPTG and stop further
synthesis of DrrAB. The expression of FtsH was induced by arabinose for 1 hour at 42 °C, and
the cells were subjected to the Dox efflux assay. To maintain the chromosomally-encoded FtsH
in an inactive conformation, the temperature was maintained at 42 °C throughout the duration of
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the experiment. As previously seen in Fig. 8B, simultaneous expression of DrrAB and FtsH
resulted in restoration of Dox efflux (Fig. 8C; 797/AB/pUCftsH, column 3). More interestingly,
however, even greater restoration of the DrrAB-mediated Dox efflux was seen when FtsH was
induced after DrrAB proteins had been pre-synthesized in these cells (Fig. 8C,
797/AB/pBADftsH+ara, column 5). In the absence of arabinose induction of FtsH, much lower
restoration of Dox efflux was seen (Fig. 8C, 797/AB/pBADftsH – ara, column 4). These data,
therefore, show that the sequential expression of DrrAB and FtsH can still restore the function of
the previously misfolded DrrAB proteins to the same (or even higher) extent as seen with
simultaneous expression.
Finally, the effect of over-expression of FtsH on Dox efflux function of DrrAB expressed
at different temperatures was investigated. Irrespective of whether the DrrAB proteins were
induced at 30 °C, 37 °C, or 42 °C in FtsHts cells, simultaneous expression of FtsH resulted in a
very similar final Dox efflux efficiency (Fig. 8D). At 42 °C, co- expression of FtsH enhanced
Dox efflux of misfolded DrrAB 5-fold (compare columns 3 and 6), yielding about 45% Dox
efflux efficiency. Interestingly, over-expression of FtsH at 30 °C or 37 °C reduced the efficiency
by about half (compare columns 1-2 with 4-5), once again yielding final Dox efflux efficiency of
about 45%. These results imply that FtsH produces an optimal level of functional complexes in
the membrane perhaps by exerting both proteolytic and refolding effects concurrently.
2.4

Discussion
Non-native proteins, especially unassembled membrane proteins, interfere with cellular

processes and are known to become toxic to the cells. Therefore, quality control systems,
consisting of chaperones and proteases, play essential roles by monitoring their folding and
either refolding or degrading misfolded proteins (78-80). Hsp60 (GroEL/ES) and Hsp70 (DnaK)
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proteins provide classical examples of ATP-dependent chaperones which prevent aggregation of
newly translated proteins and promote their refolding (79). A special class of chaperones (e.g.
ClpB in bacteria and its homologs Hsp78 and Hsp104 in eukaryotes) is known to resolubilize
protein aggregates and, in cooperation with the Hsp70 chaperones (specifically DnaKJE), can
result in regaining function of the affected protein (72). On the other end of the spectrum are
proteins classically defined as proteases, for example Lon, ClpA/P, ClpX/P and FtsH, whose
major function is considered to be removal of irreversibly damaged proteins from the cell
(63,71,81). Despite their differences, however, both classical chaperones and proteases share
common features.

For example, both have the ability to recognize and bind non-native

polypeptides and both bring about unfolding of their substrates, which are subsequently refolded
(by a chaperone) or degraded (by a protease)(69,79,82).

Because of the ATP-dependent

unfolding function of AAA+ proteases, it has been speculated that they may also have the ability
to refold substrate proteins and may participate in protein biogenesis. However, very little direct
evidence is available for the role of FtsH or other AAA+ proteases in biogenesis, especially of
membrane protein complexes. In this study, we provide clear evidence that the E. coli FtsH is
able to both degrade and refold misassembled DrrAB proteins, resulting in regaining the Dox
efflux function of the membrane complex.
We show that in the absence of the DrrA protein, DrrB acquires an FtsH-sensitive
conformation and is completely proteolyzed. However, in the absence of functional FtsH, the
DrrB protein accumulates even in the absence of DrrA confirming that FtsH monitors the folding
status of DrrB and removes it if it is improperly assembled. The molecular details of proteolysis
of DrrB by FtsH are currently unknown, however based on the prevalent model for its action
(65,83) we assume that FtsH could initiate proteolysis of DrrB either at the N- or the C-terminal
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end (both of which are found in the cytoplasm, (84)). Cross-linking studies previously showed
that the N terminus of DrrB is the major site of interaction with DrrA (61,84); therefore we
propose that proteolysis of DrrB initiates at its N- terminal tail, and binding of DrrA to this
region of DrrB protects it from proteolysis by FtsH.
Interestingly, we found that the function of FtsH is not limited to proteolysis of
unassembled DrrB, but it also plays an essential role in folding and assembly of the DrrAB
complex. This conclusion is supported by several lines of evidence presented in this paper.
First, the expression of DrrA and DrrB together in FtsHts cells at 42 °C (which results in
inactivation of FtsH) was found to be growth inhibitory (Fig. 3B) suggesting that the complex is
improperly assembled in the absence of a functional FtsH. Second, the rate of assembly of the
DrrAB complex in the FtsHts cells at 30 °C was found to be significantly reduced as compared to
the wild-type cells (Fig. 5). Third, functional analysis showed complete absence of the DrrABmediated Dox efflux in FtsHts cells under conditions of FtsH inactivation, suggesting that most
or all of the DrrAB proteins expressed in these cells at 42 °C are misassembled. By contrast, the
DrrAB proteins expressed in wild-type cells at 42 °C retained on average 85-90% of the Dox
efflux activity (Fig. 8A). Finally, co-expression of FtsH in trans in FtsHts cells restored the
ability of DrrAB to carry out Dox efflux, confirming that FtsH facilitates assembly of the DrrAB
complex (Fig. 8B). Nevertheless, this result was surprising because FtsH contains a functional
proteolytic domain. It’s overexpression in FtsHts cells results in proteolysis of the misfolded
DrrAB proteins (as seen in Fig. 4), however the data in Fig. 8B show that FtsH also facilitated
some folding resulting in about 45% recovery of the Dox efflux activity. Either the AAA
domain by itself or the GroESL chaperone was unable to complement the Dox efflux function of
DrrAB in FtsHts cells, even though each was able to alleviate the growth defect. Therefore,
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together these data suggest that both the AAA and the protease domains of FtsH are essential for
promoting functional assembly of DrrAB.
The most crucial evidence for the refolding function of FtsH, however, came from the
sequential expression studies. Irrespective of whether FtsH was expressed simultaneously with
DrrAB or expressed after the non-functional DrrA and DrrB proteins had already accumulated in
FtsHts cells, it was able to restore the function of the complex (Fig. 8C), thus showing
conclusively that FtsH not only facilitates assembly of the DrrAB complex but it is also actively
involved in refolding previously misassembled DrrAB proteins. Interestingly, we also found that
the sequential expression of DrrAB and FtsH resulted in a significantly higher recovery of the
Dox efflux function of DrrAB as compared to simultaneous expression (Fig. 8C). This finding
suggests that FtsH treats its substrate differently during its synthesis as compared to after it has
already been synthesized.
In summary, our studies confirm that the AAA domain of FtsH can recognize and bind
substrates and change their conformation, which is in agreement with the previous studies (75).
However, we also show that the two activities (ATPase and proteolytic) of FtsH must be present
simultaneously and occur in a coordinated manner to facilitate assembly and refolding of DrrAB.
Much more extensive analysis will be required in the future to understand the nature of the
molecular processes involved in refolding of DrrA and DrrB and to determine if other factors
also play a role in the assembly of the DrrAB complex. Further studies will also provide clues
about how degradation and assembly of multi-subunit complexes are regulated, and whether
other AAA+ proteases may also contain chaperone activity.

This study raises intriguing

questions about the distinction between classical chaperones like GroESL (that can prevent
aggregation of many proteins) and the classical proteases like FtsH that not only carry out
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proteolysis but also actively participate in refolding of their specific substrates, as shown in this
study. Bukau and Mogk previously (79) coined four terms to describe the various activities of
chaperones and proteases: Holders (small heat shock proteins, Hsps), Folders (GroESL and
DnaK), Unfolders (ClpA, ClpX, and ClpB), and Proteases (Lon, ClpP, and FtsH). In light of the
findings reported in this article, we propose a new term ‘Specific Refolder’ to describe the
function of FtsH and possibly other AAA+ proteases that may be shown in the future to contain
such an activity.

28

Table 2.1 Baterial strains, plasmids and anti-sera
Name

Description
Bacterial Strains
K-12 Δ(lac-pro) supE thi hsdD5/F’ tra36 proA+B+ lacIq
TG1
F- recA1 hsdR (rK12- mK12+) (DE3) (Rif R)
HMS174(DE
lacZΔM15
F-, zhd-33::Tn10, araD139,
(argF-lac)U169, rpsL150, rpsE,
AR796
3)
F , zhd-33::Tn10, araD139, (argF-lac)U169, rpsL150, rpsE,
AR797
relA1, f1bB5301,
deoC1,zba-1091::
ptsF25, rbsR,
zgj3198::Tn10kan.
Δlon-510,
ΔTn10(λ)
SG1110
relA1,
f1bB5301,
deoC1,
ptsF25,
rbsR,
zgj3198::Tn10kan.
Δarg, clpA319:: Δkan
SG1126
Plasmids
ftsH1
Cloning vector, pACYC184 derivative, Cmr
pSU2718
groES/groEL in pHSG575, Cmr
pKY326
drrAB in pSU2718, Cmr
pDX101
drrB in pSU2718, Cmr
pDX103
ftsH in pUC18, Ampr, restriction sites: EcoRI, HindIII
pUCftsH
pUCftsH(K19 pUC18 containing ftsH with mutation of Lys198 to Asn, Ampr
pUCftsH(HE pUC18 containing ftsH with mutations of His417Glu418His421
8N)
pUC18 containing ftsH with deletion of proteolytic domain,
pUCftsH(AA
417
418 r 421
GlnAmp
Ala, restriction
, Ampr sites: NdeI,
H)
groES/groELtoinAla
pUC18,
pUCgroESL
r
A)
ftsH in pET28a withAmp
C-terminal histag, Kanr
pETftsH
HindIII
ftsH(K198N) in pET28a
with C-terminal histag, Kanr
pETFftsH(K1
ftsH(HEH) in pET28a with C-terminal histag, Kanr
pETftsH(HEH
98N)
ftsH(AAA) in pET28a with C-terminal histag, Kanr
pETftsH(AAA
)
ftsH in pBAD/HisA, Ampr
pBADftsH
)

Reference or

Table 2.2 The ATPase activity of purified FtsH and its variants
FtsH Variant
Wild-type FtsH
FtsH(K198N)
FtsH(HEH)
FtsH(AAA)

ATPase activity (nmol Pi/min/mg)
139.5
18.1
147.8
155.6

Source
(85)
(85)
(54)
(54)
(86)
(86)
(59)
(76)
(59)
(59)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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Figure 2.1 Role of DrrA and FtsH in stable maintenance of DrrB

FIGURE 2.1 Role of DrrA and FtsH in stable maintenance of DrrB. (A) DrrA is required
for stable expression of DrrB. Wild-type E.coli (TG1) cells expressing DrrAB (pDX101) or
DrrB alone (pDX103) were grown at 37° C to mid-log phase (A600nm=0.6) and induced with 0.25
mM IPTG for 3 h. 30 µg membrane proteins were loaded onto 12% SDS-PAGE gels, followed
by Western blotting against anti-DrrA (upper panel) and anti-DrrB (lower panel) antibodies. (B)
FtsH is responsible for proteolysis of unassembled DrrB. Wild-type E. coli (796) or the E.
coli 797 (ftsHts) cells expressing DrrAB (pDX101) or DrrB alone (pDX103) were grown at 30 °C
to mid-log phase and induced with 0.25 mM IPTG at either 30 °C or 42 °C for 3 h. Western blot
analysis of the membrane fraction was carried out as in Fig. 1A. (C) ClpA/P or the Lon
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protease is not involved in quality control of DrrB. Wild-type E. coli (796), E. coli 797
(ftsHts), E. coli SG1110 (Lon-), and E. coli SG1126 (ClpA-) cells expressing DrrAB (pDX101) or
DrrB alone (pDX103) were grown at 30 °C or 37 °C to mid-log phase and induced with 0.25
mM IPTG at either 42 °C or 37 °C for 3 h, as indicated. Analysis was carried as described in (B)
above.

Figure 2.2 Western blot analysis of the cytosol, membrane, and inclusion body fractions of
E. coli 796 or 797 cells expressing DrrAB at 30 °C or 42 °C.
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FIGURE 2.2 Western blot analysis of the cytosol, membrane, and inclusion body fractions
of E. coli 796 or 797 cells expressing DrrAB at 30 °C or 42 °C. Wild-type E. coli 796 or the
E. coli 797 (ftsHts) cells expressing DrrAB (pDX101) were grown at 30 °C to mid-log phase and
induced with 0.25 mM IPTG at either 30 °C or 42 °C for 3 h. Cell fractions were prepared, as
described under Methods. 20 µg of each fraction was loaded onto 12% SDS-PAGE gels,
followed by Western blotting against anti-DrrA (upper panel) and anti-DrrB (lower panel)
antibodies. (m, membrane; c, cytosol; IB, inclusion body). Note that the anti-DrrB antibody is
an anti-peptide antibody, therefore it shows some cross-reactivity with epitopes in other E. coli
proteins, as explained in a previous publication (59).

Figure 2.3 Growth inhibition resulting from expression of DrrB alone or DrrAB together in E.
coli 797 cells can be relieved by the overexpression of FtsH or GroESL.
These data were contributed by Wen Li and Divya K. Rao
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FIGURE 2.3 Growth inhibition resulting from expression of DrrB alone or DrrAB together
in E. coli 797 cells can be relieved by the overexpression of FtsH or GroESL. (A) Effect of
overexpression of FtsH or GroESL on growth of 797 cells expressing DrrB. 797 cells
containing pDX103 (DrrB) and pUCftsH or pUCgroESL were grown at 30 °C and induced at 42
°C, as in Fig. 1B. The growth was monitored at O.D. 600 nm for four hours after induction. (B)
Effect of overexpression of FtsH or GroESL on growth of 797 cells expressing DrrAB. 797
cells containing pDX101 (DrrAB) and pUCftsH or pUCgroESL were anayzed, as described in
(A) above. (C) Quantitation of the growth of 796 or 797 cells expressing DrrB or DrrAB at
4 hours after induction. The growth of the sample #1 at 4 hours in Fig. 3A or 3B was
designated as 1.0. The relative growth of each culture at 4 hours was calculated. The histogram
represents an average of 3 experiments. Columns 1-9 correspond to the cultures 1-9 in Figs 3A
(filled) and 3B (open). (D) Western blot analysis. The membrane fractions were prepared from
sample #s 6-9 collected at the 4 hour time point in Fig. 3A and 3B. Western blot analysis was
carried out as in Fig. 1(A).
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Figure 2.4 FtsH preferentially degrades misfolded DrrAB.

FIGURE 2.4 FtsH preferentially degrades misfolded DrrAB. (A) E. coli 796 or 797 cells
containing pDX101(DrrAB) and pUCftsH were grown and analyzed by Western blotting, as in
Fig. 1A. (B) Quantitative analysis of the amounts of DrrA and DrrB. The intensity of the
bands on the nitrocellulose membrane in Fig. 4A was determined by densitometric scanning.
The intensity of DrrA and DrrB in lane 1 was designated as 1. The data represent an average of
3 experiments. Columns 1-8 correspond to the lanes 1-8 in Fig. 4A. (C), (D) and (E) In vivo
FtsH proteolytic assay. The assay was carried out as described under Methods. The membrane
fractions were prepared from the cells collected at the indicated time points after addition of
arabinose. 20 µg total membrane protein was loaded onto 12% SDS-PAGE, followed by
Western blot with anti-DrrA, anti-DrrB, or anti-FtsH antibodies. The intensity of the bands on
the nitrocellulose membrane was determined by densitometric scanning. The intensity of DrrA
and DrrB on the membrane at 0 min was designated as 1.0. (C) Quantitation of DrrA in the
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membrane at the indicated time points after addition of arabinose. The data shown represent an
average of 3 experiments. (D) Quantitation of DrrB in the membrane. (E) Western blot analysis
showing amount of FtsH present in the membrane at various times after addition of arabinose.
Top panel: cells containing pBAD vector only. Bottom panel: cells containing the plasmid
pBADftsH.

Figure 2.5 FtsH promotes assembly of the DrrAB complex
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FIGURE 2.5 FtsH promotes assembly of the DrrAB complex. (A) E. coli 796 or 797 cells
expressing DrrAB were grown at 30 °C to mid-log phase and the culture was divided into two
halves. One half was induced with 0.25 mM IPTG at 30° C (lanes 1-3 for 796 and lanes 7-9 for
797) and the other half was induced at 42 °C (lanes 4-6 for 796 and lanes 10-12 for 797).
Aliquots of each sample were collected at 30 min intervals. Hours of induction are shown at the
top of the gel. 0 hour represents A600nm = 0.6 at which time IPTG was added. Western blot
analysis was carried out as in Fig. 1A. (B) The quantitative analysis of DrrA and DrrB. The
intensity of bands on the nitrocellulose membrane was determined by densitometric scanning.
The intensity of DrrA and DrrB in lane 1 was designated as 1. The data represent an average of
3 experiments.

Figure 2.6 In vitro digestion of α-casein by purified FtsH or FtsH(HEH)
FIGURE 2.6 In vitro digestion of α-casein by purified FtsH or FtsH(HEH). (A) α-casein was
mixed with purified wild-type FtsH or FtsH (HEH) protein in the protease buffer as described in
the Methods. The samples were analyzed by 12% SDS-PAGE, followed by Coomassie Brilliant
blue staining. (B) Quantitative analysis of the amounts of α-casein. The intensity of the
bands on the nitrocellulose membrane was determined by densitometric scanning. The intensity
of α-casein in lane 1 was designated as 1. The intensities represent an average of 3 experiments.
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Figure 2.7 The AAA domain of FtsH is sufficient to complement the growth defect
resulting from the expression of DrrAB in 797 cells.
These data were contributed by Wen Li and Divya K. Rao
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FIGURE 2.7 The AAA domain of FtsH is sufficient to complement the growth defect
resulting from the expression of DrrAB in 797 cells. E. coli 797 cells containing the drrAB
genes (pDX101) and the wild-type or a mutated version (K198N, HEH, or AAA subclone) of the
ftsH gene on a compatible plasmid were grown at 30 °C and induced at 42 °C, as in Fig. 1B. (A)
Growth analysis at 600 nm. (B) Western blot analysis. Membranes prepared from the cells
collected at the 3 hour time point were analyzed, as in Fig. 1A. (C) Quantitative analysis of
DrrA and DrrB. The intensity of the bands on the nitrocellulose membrane in Fig. 7B was
determined by densitometric scanning. The intensity of DrrA and DrrB in lane 1 was designated
as 1.0. The data shown represent an average of 3 experiments. The columns 1-8 correspond to
samples 1-8 in Fig. 7B.

Figure 2.8 DrrAB-mediated Dox efflux.
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FIGURE 2.8 DrrAB-mediated Dox efflux. (A) Dox efflux in E. coli 796 or 797 cells. The
cells containing pDX101 (DrrAB) or the empty vector were grown at 30 °C to mid-log phase and
induced with 0.1 mM IPTG at either 30 °C or 42 °C for 1 h. The washed cells were loaded with
Dox, and efflux was initiated by addition of glucose and detected fluorometrically. The slope of
the efflux curve of sample 1 in each panel was designated as 1.0. The efficiency of Dox efflux
was then calculated by dividing the slope of each efflux curve by the slope of sample 1. The
average data obtained from three independent experiments are shown in the histograms. (B)
Complementation of the DrrAB-mediated Dox efflux in 797 cells by simultaneous
overexpression of wild-type FtsH or its variants. E. coli 797 cells containing
pDX101(DrrAB) and pUCftsH (wild-type FtsH), pUCftsH(K198N), pUCftsH(HEH),
pUCftsH(AAA) or pUCgroESL, were analyzed as described under (A) above. (C) Effect of
sequential expression of DrrAB and FtsH on complementation of Dox efflux. E. coli 797
cells containing pDX101 (DrrAB) and pBADftsH were grown at 30 °C to mid-log phase and
induced with 0.1mM IPTG for 1 h at 42 °C. The cells were washed extensively to remove IPTG
and divided into two halves. One half was kept at 42 °C for 1 h without any induction (-ara, 42
°C) and the other half was induced by 1% arabinose at 42 °C (+ara, 42 °C) for 1 h. As controls,
796/AB, 797/AB and 797/AB/pUCftsH were grown at 30 °C to mid-log phase and induced with
0.1 mM IPTG at 42 °C for 2 h. The cells were loaded with Dox, and efflux was measured. The
data were analyzed as described under (A) above. (D) Effect of simultaneous over-expression
of FtsH on Dox efflux by DrrAB proteins expressed at different temperatures. 797 cells
containing pDX101 (DrrAB) and pUCftsH were grown at 30 °C to O.D. 0.6, induced with 0.1
mM IPTG at 30 °C, 37 °C or 42 °C for 1 h, and analyzed as in (A) above.
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3 THE DrrAB SYSTEM OF STREPTOMYCES PEUCETIUS IS A MULTI-DRUG
TRASNPORTER OF A BROAD SUBSTRATE SPECIFICTY
2.5

Introduction
Multidrug resistance (MDR) has emerged as a major clinical problem in recent years both

for the treatment of infectious diseases and for chemotherapy of cancer. Although many
different mechanisms for drug resistance are known, a common strategy consists of active efflux
of drugs from the cells (87). Drug transporters are categorized into either single-drug efflux
systems (which are specific for a drug or a group of drugs) or multi-drug efflux systems that
exhibit a broad specificity and can transport structurally and functionally unrelated compounds.
These proteins function as either primary active (belonging to the ATP Binding Cassette
superfamily) or secondary active transporters (88). The phenomenon of multidrug resistance
was first characterized in mammalian cancer cells, where exposure to anticancer drugs was seen
to result in over-expression of ABC-type efflux pumps, such as P-glycoprotein and MRP1 (88).
These proteins have since been shown to transport hundreds of structurally unrelated
compounds, including amphipathic anti-cancer drugs, peptides, and fluorescent dyes, etc., thus
conferring MDR in cancer cells. MDR is also widespread among bacteria - the best known ABC
family members include the bacterial proteins LmrA and LmrCD in L. lactis, Sav1866 in S.
aureus, and MsbA in E. coli.
While most of the ABC proteins mentioned above have served as useful models to
characterize and understand the basis of MDR (7,88), the most extensive biochemical analysis of
the nature of multidrug specificity has been carried out with Pgp (89,90). Together the analyses
carried out by many different groups suggested that Pgp contains a large drug binding chamber
which can accommodate several drugs simultaneously. It was also suggested that the drug

40

binding chamber in Pgp is lined by several trans-membrane (TM) helices, including TMs 4-6 in
TMD1 and TMs 9-12 in TMD2 (89). Most recently, the crystal structure of Pgp confirmed many
findings of the biochemical analysis and showed that Pgp indeed contains a large and flexible
drug binding cavity made of mostly hydrophobic and aromatic residues (42). Different drugs
were seen to interact with residues in different parts of the flexible cavity, mostly through
hydrophobic interactions, thus providing an explanation for the poly-specific nature of Pgp. The
crystal structure of Pgp also revealed that some drugs were bound to a single site, while some
others bound to two different locations within the cavity. The drug binding cavity of Pgp was
found to reside within the cell membrane, and it showed the presence of two portals formed by
TMs 4 and 6 and TMs 10 and 12 which allow direct entry of hydrophobic molecules from the
membrane (42). This observation supports previous models, which proposed that Pgp can
extract drugs directly from the lipid bilayer and remove them by a hydrophobic vacuum cleaner
mechanism (17). The crystal structure of another MDR protein, AcrB, a secondary-active
transporter, is also available. This structure also showed the presence of a very large central drug
binding cavity, which could accommodate several ligand molecules simultaneously (91).
However, the drug binding cavity, though present in the membrane, was found to be accessible
to the periplasmic domain. Thus, in contrast to Pgp (where the drug portals are located in the
membrane), the periplasmic region of AcrB seems to play a major role in determining substrate
specificity, suggesting differences between the mechanisms of different MDR proteins.
The bacterial ABC drug transporters that have also been studied in significant detail
include the E. coli ABC transporter MsbA (responsible for export of Lipid A, the core moiety of
LPS), L. lactis homologue LmrA and S. aureus Sav1866 (5,7,92). All of these proteins have
been shown to transport multiple drugs. Interestingly, MsbA was found to contain overlapping
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substrate specificity with LmrA and Sav1866 (93). Some newly identified members, such as
VcaM from Non-O1 Vibrio cholerae and the YccC (BmrA) from Bacillus subtiliswere also
shown to transport multiple drugs (94,95). Therefore, a significant progress has indeed been
made in understanding the phenomenon of multidrug resistance. However, the available
information is based on the analysis of only a handful of drug transporters described above.
Most other annotated drug transporters, especially those found in the antibiotic/drug producer
organisms, have not been analyzed for their ability to confer MDR. Moreover, not much is
known about why and how the ability to confer multidrug resistance evolves.
In this study, we analyzed the ABC transporter DrrAB, which confers self-resistance to
two related anticancer antibiotics doxorubicin (Dox) and daunorubicin (Dnr) in the producer soil
organism Streptomyces peucetius. The genes for this system are present in an operon located
within the gene cluster for biosynthesis of Dox and Dnr, therefore they code for a dedicated
transporter for these antibiotics. The DrrAB system represents the simplest form of an ABC
drug transporter, which is assembled from two molecules each of DrrA (the catalytic subunit)
and DrrB (integral membrane subunit) (49). In the mammalian Pgp, the two catalytic and two
integral membrane domains are naturally fused into a single large polypeptide, possibly the result
of an evolutionary gene fusion event (4). Both DrrAB and Pgp confer resistance to the
anticancer agents Dox and Dnr: DrrAB in the producer organism and Pgp in cancer cells.
Therefore, the overall structure and function of the DrrAB transporter bears significant similarity
to Pgp even though these two transporters belong to different classes of ABC proteins (50).
Subcloning of the drrAB locus in E. coli was previously shown to confer doxorubicin resistance
in this host (48). It was also previously shown that the DrrAB system confers resistance to Dox
by an energy-dependent efflux mechanism (58). However, it is not known if this system is
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specific for Dox and Dnr, or if, like Pgp, it can also recognize and transport multiple drugs.
Since this is a prototype drug resistance mechanism found in the producer organism, analysis of
this system could shed light on the nature of substrate specificity and elucidate how the ability to
confer multidrug resistance evolves in proteins.
In this paper, we provide in-depth characterization of drug transport by the DrrAB system
and show that, contrary to the generally held assumption, this system forms a multidrug
transporter. Using both E. coli whole cells and inside-out membrane vesicles (IOVs), it is shown
that the DrrAB system can efficiently transport not only Dox, but also Hoechst 33342 and
ethidium bromide, two substrates most commonly used to establish the MDR phenotype (5,7,27).
We also found that the DrrAB-mediated Dox efflux is inhibited by a number of other wellcharacterized MDR substrates, such as verapamil, rifampicin, vinblastine and colchicine,
suggesting that these drugs are also substrates of the DrrAB pump. Interestingly, DrrABmediated efflux could be coupled to the energy of either ATP or GTP hydrolysis, and, as
expected, the function of this transporter was found to be completely independent of the proton
motive force (pmf). Since multiple drugs were found to inhibit Dox efflux by the DrrAB system,
kinetics analysis was carried out to understand the mechanism of inhibition and interaction of
drugs with DrrAB. Our studies revealed that inhibition of Dox efflux by Hoechst 33342 and
rifampicin occurs by a competitive mechanism, whereas verapamil inhibits Dox transport by a
non-competitive mechanism, suggesting that the DrrAB transporter may contain at least two
drug binding sites. The findings of this paper demonstrate for the first time that the dedicated
Dox transport system, DrrAB, can recognize and transport multiple drugs. This study highlights
overlaps between the substrate specificity of the DrrAB system and Pgp and points to a common
mechanism, and perhaps origin, for most MDR proteins.
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2.6

Materials and Methods

Materials used – verapamil, vinblastine, rifampicin, doxorubicin hydrochloride, ethidium
bromide, quinine, quinidine, colchicine, succinate, sodium fluoride, NADH (β-Nicotinamide
adenine dinucleotide reduced disodium salt hydrate), ATP, GTP, and sodium o-vanadate were
purchased from Sigma Aldrich. Hoechst 33342, rhodamine 123, rhodamine 6G, rhodamine B,
and TMRM (Tetramethylrhodamine) were obtained from Life Technology. Creatine kinase and
creatine phosphate were purchased from Roche Diagnostics.
In vivo Dox efflux in cells – E. coli LE392ΔuncIC cells (Table 1) containing either vector
pSU2718 or pDX101(pSU2718/drrAB) were grown in 200 ml TEA medium [50 mM
triethanolamine HCl, pH 6.9, 15 mM KCl, 10mM (NH4)2SO4, 1mM MgSO4] supplemented with
0.5% (w/v) glycerol, 2.5 µg/ml thiamine, 0.5% (w/v) peptone and 0.15% (w/v) succinate to midlog phase and induced with 0.1 mM IPTG for 1 hr. The harvested cells were washed twice and
resuspended in 100 µl TEA buffer. 10 μl of the cell suspension from above was incubated in 3
ml of TEA medium containing 10 μM doxorubicin and 5 mM 2,4-dinitrophenol for 11 h at 37
°C. The loaded cells were washed twice with 0.1 mM MOPS buffer, pH 7.0 and resuspended in
3 ml of MOPS buffer containing 2 mM MgSO4. The fluorescence spectra were recorded on an
Alphascan-2 spectrofluorometer (Photon Technology International, London, Ontario, Canada).
The excitation wavelength for doxorubicin was 480 nm, and emission was monitored at 590 nm.
The excitation and emission slit widths were both set at 1.00 mm, and a time-based script was
run. After an initial recording of fluorescence for 100 s at 37 °C, energy was provided in the
form of either 20 mM glucose or 20 mM succinate, and recording was continued for an
additional 400 s. The rate of Dox efflux was determined from the slope in the steady-state range
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(300 s to 500 s). Where indicated, 10 mM sodium fluoride was added as inhibitor of ATP
synthesis.
In vivo ethidium bromide (EtBr) efflux in cells – E. coli LE392ΔuncIC cells containing the
indicated plasmid were grown, induced, and loaded with various concentrations (1 µM to 100
µM) of EtBr, as described above, except that the loading time used was 1 hr at 37 °C. The
loaded cells were washed twice with 0.1 mM MOPS, pH 7.0 and resuspened in 3 ml MOPS
buffer containing 2 mM MgSO4. EtBr efflux from loaded cells was measured fluorometrically
(exi, 500 nm; emi, 580 nm) on an Alphascan-2 spectrofluorometer (Photon Technology
International). After 100 s, energy was provided in the form of 20 mM glucose. The recording
was continued for additional 400 s. The rate of EtBr efflux was determined from the slope in the
steady-state range (300 s to 500 s).
Preparation of inside-out membrane vesicles (IOVs) – E. coli LE392ΔuncIC cells containing
indicated plasmids were grown in 1 L LB medium at 37 °C until mid-log phase and induced with
0.25 mM IPTG at 37 °C for 3 hr. The cells pellet was re-suspended in 20 ml 1xPBS buffer, pH
7.4 and lysed with French Press at 16,000 p.s.i. twice. The membrane fraction was prepared
according to the previously published protocol (49), except that the membrane vesicles were
washed twice with 20 ml 1xPBS buffer.
In vitro Dox efflux in IOVs and kinetic analysis – 250 µg IOVs were resuspended in 3 ml 1x
PBS buffer, pH 7.4 supplemented with 0.1 mg/ml creatine kinase and 5 mM creatine phosphate.
Dox was added to a final concentration of 1.0 µM, or as indicated. The fluorescence spectra
were recorded on an Alphascan-2-spectrofluorometer with excitation wavelength of 480 nm and
emission wavelength of 590 nm. The excitation and emission slit width were set to 1.00 mm and
data were collected at 0.1-s intervals. After 100 s, the detection was paused, 1 mM Mg2+ and 1
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mM ATP, pH7.5 were added into the reaction and the detection was continued for additional 400
s. Where indicated, ATP was substituted with 1 mM GTP or 5 mM NADH. The rate of Dox
transport was determined from the slope of the initial linear range between 100 s and 200 s. To
determine the kinetics of Dox transport, efflux was measured at a wide range of Dox
concentrations (0.1 µM to 6 µM). The data were fitted by the Michaelis–Menten equation (V =
Vmax[S]/(Km) + [S]) by Sigma Plot Kinetics software in Single-Substrate Format.
In vitro Hoechst 33342 Efflux in IOVs – The DrrAB-mediated efflux of Hoechst 33342 was
studied in IOVs, as described above for Dox Efflux with some modifications. Briefly, 250 µg
IOVs were resuspended in 3 ml 1x PBS buffer, pH 7.4 supplemented with 0.1 mg/ml creatine
kinase and 5 mM creatine phosphate and various concentrations of Hoechst 33342 (0.1 µM to
2.5 µM). The excitation and emission wavelengths of Hoechst 33342 were 355 nm and 457 nm,
respectively. The rate of Hoechst 33342 transport was determined from the initial slope of the
linear range between100 s to 200 s.
Vanadate inhibition of Dox efflux in IOVs – 250 µg IOVs were resuspended in 3 ml 1x PBS
buffer, pH 7.4 supplemented with 0.1 mg/ml creatine kinase, 5 mM creatine phosphate, 1 µM
Dox, and various concentrations of sodium o-vanadate (0 µM – 100 µM). The measurement of
Dox efflux was performed, as described above. The rate of Dox transport was determined from
the slope of the linear range between 100 s and 200 s.
Determination of IC50 – 250 µg IOVs were resuspended in 3ml 1xPBS buffer, pH 7.4
supplemented with 0.1 mg/ml creatine kinase and 5 mM creatine phosphate, 1 µM Dox, and
various concentrations of the inhibitory drug. The measurement of Dox efflux was performed, as
described above. The rate of Dox transport was determined from the slope of the initial linear
range between 100 s and 200 s. Designating the efflux rate of the sample without inhibitor as
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1.0, the relative rate of each sample was calculated. The average data of three independent
experiments were plotted by ‘Scatter Plot with simple error bars’ in Sigma Plot 11.0 software
and fitted by the dynamic curve fit (equation: y = ae-bx, x: concentration of inhibitor; y: relative
rate). The IC50 value was determined based on the concentration of the drug that brings about
50% inhibition of the DrrAB-mediated Dox efflux at a Dox concentration of 1 µM.
Kinetics of Dox efflux inhibition by known MDR substrates – To study the kinetic inhibition
of Dox efflux by Hoechst 33342, four different concentrations of Dox (0.25, 0.5, 0.75 and 1.0
µM) were individually mixed with a fixed concentration of Hoechst 33342 in 1x PBS buffer
containing 250 µg IOVs, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate. In total, four
different concentrations of Hoechst 33342 (0, 0.2, 0.6 or 0.8 µM) were studied. Similar assays
were set up to study kinetics of Dox inhibition by different drugs. Initial rate of Dox transport
was determined, as described above. The rate of Dox transport obtained with 1 µM Dox and 0
µM Hoechst 33342 (or another drug) was designated as 1.0. The relative rates were then
calculated for each efflux curve, and the data were plotted by Lineweaver-Burk plot using
SigmaPlot - Kinetics software in Single-Substrate/Single-Inhibitor Kinetics Format. The error
bars represent three independent experiments. The type of inhibition was determined based on
the AICc value (Akaikes Information Criterion corrected); lower AICc values correspond to
better fits to the data.
Point Mutations in DrrA – Site-directed mutagenesis of the drrA gene was carried out by a
QuikChange Multisite-directed mutagenesis kit (Stratagene, La Jolla, CA). Using pDX101
(pSU2718/drrAB) plasmid as the template, Gln197, located in the Switch motif of DrrA, was
changed to Histidine. The resulting plasmid was named pDX101(Q197H). Another plasmid,
generated by substituting Tyr198 to Arginine, was named pDX101(Y198R). Double mutations
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of Gln197Tyr198 to His197Arg198 and His197His198 were also created, and these plasmids
were named pDX101(Q197H/Y198R; HR) and pDX101(Q197H/Y198H; HH). Other mutations
used in this study were described previously (Table 1).
ATPase activity in IOVs - 7.5 µg IOVs expressing either wild type DrrAB or DrrAB with
mutations in the Switch motif were incubated in 1 ml reaction mixture containing 50 mM MOPs,
pH 7.5, 1mM dithiothreitol, 10µl PK/LDH enzyme (Sigma Aldrich), 5 mM ATP, 0.25 mM
NADH (β-Nicotinamide adenine dinucleotide) and 1.25 mM PEP[phosphor(enol)pyruvic acid] at
37 ºC for 10 min, as described previously (30). The reaction was started by addition of 2.5 mM
MgCl2. The optical density at 340 nm was monitored for 10 min using Shumadzu UV1601
spectrophotometer and the UV probe 2. 20 Kinetics software. The slope of the linear portion of
each curve (between 200 s and 400 s) was used to calculate ATPase activity. The activity of the
control IOVs (without DrrAB) was subtracted from the activity of each test sample to obtain
DrrAB-specific activity. Relative activity was then calculated by dividing the activity of each
sample by the activity of the wild type sample.
2.7

Results

Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro conditions –
An in vivo assay for studying DrrAB-mediated Dox efflux was reported previously (58,61) and is
shown in Fig. 1A. In this study, we established conditions to study DrrAB-mediated Dox efflux
under in vitro conditions using E. coli inside out membrane vesicles (IOVs) (Fig. 1B). Both in
vivo and in vitro assays utilize the fluorescent nature of Dox to measure efflux in E. coli
LE392ΔuncIC cells (or IOVs). This strain of E. coli contains a deletion in the unc genes; as a
result it is unable to carry out synthesis of ATP using proton gradients or establish a proton
gradient by hydrolysis of ATP (96). Therefore, it is possible to establish conditions where only
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the proton motive force (pmf) or ATP is available as a source of energy (described below). Dox
is fluorescent in solution, however its accumulation inside the cells results in quenching of its
fluorescence and its efflux results in an increase in fluorescence intensity (97).
In vivo Dox efflux – The basic strategy for studying efflux under in vivo conditions consists of
loading of the de-energized cells with Dox (58), followed by addition of an energy source, which
is expected to result in efflux of Dox and an increase in its fluorescence (Fig. 1A). Under the
conditions used in our experimental system, use of succinate as energy will generate only proton
motive force while glucose will generate both pmf and ATP, therefore allowing us to
discriminate between the energy sources used by the DrrAB system. The data in Fig. 1A
compare the rate of Dox efflux in DrrAB-containing cells in the presence of glucose or succinate.
E. coli LE392ΔuncIC cells (containing empty vector) were used as negative control in these
experiments. Two conclusions can be made from the data shown in Fig. 1A. First, the rate of
Dox efflux by the DrrAB-containing cells in the presence of glucose is about 5-fold higher as
compared to the rate in control cells (Fig. 1A.2, compare columns 1 and 4). A small increase in
Dox efflux efficiency seen in control cells on addition of glucose is likely due to the action of
one of the several MDR pumps known to be present in E. coli (87). Secondly, in contrast to
glucose, use of succinate as energy showed no increase in fluorescence intensity in DrrABcontaining cells (Fig. 1A.1, curve 2; Fig. 1A.2, column 2), indicating that pmf does not support
Dox efflux by the DrrAB proteins. Confirmation of these results was obtained by addition of
sodium fluoride, a specific inhibitor of ATP synthesis by substrate-level phosphorylation, to
DrrAB-containing cells in the presence of glucose. The data show a drastic reduction in Dox
efflux by the DrrAB-containing cells (Fig. 1A.1, curve 3; Fig. 1A.2, column 3), resulting in the
same background levels of efflux as seen with succinate (column 2). These studies show that
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doxorubicin efflux by the DrrAB pump is solely ATP-dependent, and pmf is not required for this
process, thus highlighting similarities between DrrAB and other MDR proteins of the ABC
superfamily (6,27,98).
In vitro Dox efflux – To understand the kinetics of Dox transport, an in vitro Dox efflux assay
was optimized using inside-out membrane vesicles, as described under Methods. In this assay,
the vesicles were mixed with Dox, and efflux was initiated by addition of ATP and Mg2+.
Because of the inverted nature of the IOVs, DrrAB-mediated efflux results in accumulation of
Dox inside the vesicles which is seen as quenching of its fluorescence (Fig. 1B.1). The data in
Fig. 1B.1 show that addition of ATP/Mg2+ first results in a rapid non-specific decrease in Dox
fluorescence due to interaction between Dox and ATP (97). This quick phase is then followed
by a slower rate of quenching, which corresponds to the DrrAB-dependent efflux in the vesicles.
The initial rate of Dox efflux was therefore determined from the linear slope of the fluorescence
spectra between 100 s and 200 s. As seen in Fig.1B.1 and 1B.2, Dox transport activity in
vesicles containing DrrAB was found to be almost 12-fold higher as compared to the control
vesicles prepared from cells containing vector alone (Fig. 1B.2, compare columns 1 and 4).
Absence of either Mg2+ (column 2) or ATP (column 3) resulted in the failure of these vesicles to
transport Dox. Use of NADH as an energy source also did not support Dox efflux (column 6),
once again confirming that proton motive force is not used by the DrrAB proteins as a source of
energy. Surprisingly, when GTP was used as an energy source instead of ATP, even higher
transport activity was observed (column 5). Dox-dependent ATP and GTP binding to DrrA was
shown previously (48). Together these data indicate that either ATP or GTP (and Mg2+) can
serve as a source of energy for the Dox transport function of DrrAB.
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Kinetic Analysis of Dox efflux in vitro –To understand the kinetics of Dox efflux by the DrrAB
system, efflux was analyzed (as shown in Fig. 1B.1) at a wide range of Dox concentrations. The
initial rate (slope between 100 s-200 s) of each efflux curve was determined. Efficiency of Dox
efflux was then calculated, as described under Methods and Figure Legends. The data were
fitted to a hyperbola using the Michaelis-Menten equation (with an R2 of 0.89), yielding an
apparent Km of 0.38 µM and Vmax of 1003 (arbitrary units, a.u.) (Fig. 1C). These data showed a
linear increase in the rate of Dox transport at concentrations ranging between 0.1 µM and 1 µM,
which became saturated after 3µM. The Dox transport data could also be fitted equally well by
the Hill equation; the implication of this finding is discussed later.
Inhibition of Dox transport activity by sodium o-vanadate – Vanadate (Vi) is a known
inhibitor of the ATPase activity of ABC proteins (99-102). Since it functions as an analog of Pi,
the ADP·Vi·Mg2+ complex is trapped in the ATP binding pocket after a single catalytic turnover,
thus blocking further hydrolysis of ATP as well as drug transport. To determine if the DrrAB
system is inhibited by vanadate, Dox transport was measured in IOVs in the absence or presence
of increasing amounts of vanadate (5 µM to 100 µM). The data in Fig. 1D show that vanadate is
a potent inhibitor of the Dox transport of DrrAB, with an IC50 = 11 µM. A complete inhibition
of the Dox transport activity was seen at 100 µM vanadate. These data are consistent with the
previously reported studies on the inhibitory effect of vanadate on Pgp and MsbA (101,103).
Point mutations in the nucleotide binding domain of DrrA compromise Dox transport
activity – The N-terminal nucleotide binding domain of DrrA contains a 200 amino acids long
ABC cassette consisting of all the conserved motifs (Walker A, Walker B, Signature motif/Cloop, Q-loop, and the Switch motif/H-loop) involved in ATP binding and hydrolysis (Fig. 2A.1).
We previously reported that mutations in the conserved residues of DrrA confer Dox sensitivity

51

(104). Mutations in Walker A, as expected, also compromised ATP binding (104). Here we
evaluated the effect of several mutations on DrrAB-mediated Dox efflux in IOVs. The data in
Fig. 2B show that, as expected, single point mutations in Walker A (such as G44A, G44S or
K47R), signature (S141R), or the Walker B (E165Q) motif of DrrA result in a drastic effect on
Dox transport activity. Since the sequence of the Switch motif of DrrA is different from most
other ABC proteins (Fig. 2A), this region was analyzed in greater detail, as described below.
Most ABC proteins normally contain a highly conserved histidine residue in their Switch motif,
followed by an arginine, histidine, or a lysine (Fig. 2A.1). The conserved histidine of the Switch
motif and a conserved glutamate immediately following the Walker B motif (both are shown as
highlighted areas in Fig. 2) are together believed to be critical for formation of the active sites in
ABC proteins. Zaitseva et al recently proposed that these two residues together form a catalytic
dyad which functions in substrate-assisted catalysis (105). However, despite the high
conservation of these two residues in ABC proteins, deviations in the sequence of these motifs
are sometimes seen. Most commonly, a glutamine replaces the histidine in the Switch motif and
an aspartate replaces the glutamate in the Walker B region. When present (for example in TAP1
and LmrC), these deviations are seen to result in asymmetrical ATP binding pockets with one
site being catalytically non-functional (106,107). Interestingly, however, despite the presence of
the non-canonical glutamine residue (Q197 followed by Y198, resulting in QY sequence) in the
Switch motif of DrrA (as well as its close prokaryotic homologs, Fig. 2A.2), it is able to form a
functional drug transporter with DrrB, as seen in Fig. 1. Note that the close eukaryotic homologs
of DrrA most often contain an HH sequence in the Switch region (Fig. 2A.3), and both
prokaryotic and eukaryotic groups contain the conserved glutamate in the Walker B region
(specifically E165 in DrrA) (Figs. 2A.2 and 2A.3)
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Since histidine is conserved in the Switch of most ABC proteins, we wondered if the
DrrAB transporter will become more efficient if Q197 is substituted with a histidine or if the QY
sequence is changed to the commonly occurring sequence HR or HH. Surprisingly, we found
that the Q197H mutation in DrrA produces a drastic effect on Dox efflux, however mutation of
Y198 to Y198R retains about 35% Dox efflux function (Fig. 2C). Interestingly, a double
mutation HR (Q197H/Y198R) also resulted in Dox transport activity of about 38% indicating
that the second mutation partially masked the harmful effect of the Q197H single mutation (Fig.
2C). By contrast, the double mutation HH (Q197H/Y198H) exhibited extremely low Dox efflux
(Fig. 2C). To understand the role of Q197 and Y198 in catalysis, the effect of the abovementioned mutations on the ATPase activity of the DrrAB complex was determined. We found
that while Q197H produces a drastic effect on ATPase activity, both HR and HH double
mutations show significant ATPase activity (43% and 61%, respectively) (Figs. 2D and 2E),
indicating that the second mutation in each case partially compensates for the negative effect of
the Q197H mutation on catalysis. Overall the findings in Fig. 2 indicate that residues Q197 and
Y198 in the Switch motif of DrrA function together and that the QY sequence works much better
than the HH or HR sequence for the overall Dox efflux function of the DrrAB complex.
Interestingly, the HH double mutant still exhibits 60% ATP hydrolysis activity, which suggests
that either the QY or the HH sequence could participate in the formation of functional catalytic
sites in DrrA. However, the HH allele seems to be defective in specific communication between
DrrA and DrrB resulting in significantly reduced Dox efflux (less than 5%). Therefore the
context in which the Switch motif functions in different ABC proteins may determine the nature
of this motif. The conserved glutamate E165 present near the Walker B region served as a
control in these experiments. Analysis of the E165Q mutation showed a drastic effect on both

53

hydrolysis of ATP and Dox efflux (Figs. 2B-D), which is consistent with the critical role of this
residue previously reported in literature (108). How a glutamine residue participates in the
formation of functional ATP binding pockets in DrrA is still an open question. However, we can
draw from the analogous situations present in other ATP/GTP-binding proteins (including RecA
and H-ras p21) which contain a catalytic glutamine residue (Q194 in RecA and Q61 in H-ras
p21) in their switch II domain in the position corresponding to Q197 in DrrA (1,109,110). The
3-d structures of RecA and H-ras indicate that these glutamines show similar interactions with
the catalytic glutamate and γ phosphate of ATP to those seen with histidine in the ABC proteins,
therefore suggesting that the glutamine functions in a manner similar to histidine in producing
the overall conformation of the active site. This is consistent with our observation that either QY
or HH sequence can indeed participate in formation of the catalytic sites in DrrA although the
HH sequence is deficient in energy transduction. In summary, the analyses in Fig. 2 confirm that
a functional nucleotide binding domain of DrrA is essential for Dox efflux by the DrrAB system.
The analysis of the Switch mutations, in particular, also indicates that the in vitro efflux assay
described here can provide a sensitive and a valuable approach for elucidating the role of critical
residues in the catalytic and drug transport function of the DrrAB complex.
DrrAB-mediated Dox efflux is inhibited by multiple MDR substrates – To determine if the
DrrAB transporter can recognize and bind other known MDR substrates, inhibition of Dox efflux
by different drugs was investigated in IOVs. These assays were carried out at a wide range of
the inhibitor concentrations while maintaining a constant concentration of Dox, as described
under Methods (determination of IC50 values). The data in Fig. 3 show that many known MDR
drugs, including H 33342 (H 33342) (Fig. 3A), verapamil (Fig. 3B), and rifampicin (Fig. 3C),
inhibit DrrAB-mediated Dox efflux with high efficiency. The data in Fig 3, panel D, summarize
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the inhibitory effects of many different MDR substrates and indicate that the IC50 values vary
dramatically for different substrates. For example, H 33342, vinblastine, verapamil and
rifampicin show relatively low IC50 values, while much higher concentrations of EtBr, quinidine,
and colchicine were required for the same level of inhibition. These data suggest that the DrrAB
system has multiple substrates, which bind with varying affinities. However, whether these drugs
bind to the same site, or if there are multiple drug binding sites, can’t be ascertained from these
data. To understand the nature of drug binding, kinetics of DrrAB-mediated Dox efflux was
studied at multiple Dox concentrations in the presence of several concentrations of each
inhibitory drug, which is described below.
Kinetics of Dox Inhibition by MDR drugs – The data in Fig. 1C showed that the rate of Dox
efflux by DrrAB-containing IOVs increases linearly between 0.1 µM and 1 µM Dox
concentration, therefore four evenly distributed concentrations of Dox within this range (0.25,
0.50, 0.75, and 1.0 µM) were used in the kinetics analysis. At each concentration of Dox, efflux
was measured in the presence of our different concentrations of H 33342, verapamil, or
rifampicin. These drugs were chosen based on their low IC50 values seen in inhibition studies
(Fig.3D). (Since Dox and ethidium together were incompatible in the fluorescence-based assays
due to their overlapping excitation/emission spectra, this combination could not be used in this
study). The initial slope (100-200 seconds) for each Dox efflux curve was determined. The
slope of the Dox efflux curve at 1.0 µM Dox and 0 concentration of the inhibitor was designated
as 1, which was then used to calculate the relative slope of each curve obtained in the presence of
the inhibitor, as described under Methods. The relative slopes were plotted by the LineweaverBurk plots using the Sigma Plot kinetics software (Fig. 4). The data in Fig. 4A indicate that the
inhibition of Dox efflux by H 33342 is characteristic of competitive inhibition; the Km of DrrAB-
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mediated Dox transport increased at increasing concentration of H 33342, whereas the Vmax
remained unchanged. These data suggest that Dox and H33342 may bind to the same site in
DrrAB. The apparent inhibition constant (Ki for H33342) was found to be 0.64 µM, which
corresponds well to the IC50 value of H 33342 (Fig 3, panel D). When studying the inhibition of
Dox transport by rifampicin, a similar pattern was observed, which indicated a competitive
inhibition between Dox and rifampicin (Fig. 4C). However, the kinetics of inhibition of Dox
transport by verapamil showed a different pattern (Fig. 4B). The Vmax decreased at increasing
concentration of verapamil, while Km remained unaltered, indicating a non-competitive inhibition
between Dox and verapmail. These data suggest that verapmail may bind to both the unliganded
DrrAB and the binary DrrAB-Dox complex. The Ki value for verapamil inhibition was found to
be 9.4 µM, which also matches well to the IC50 of verapamil (Fig. 3, panel D). The observed
competitive and non-competitive inhibitions of DrrAB-mediated Dox transport in IOVs imply
that DrrAB must contain at least two drug binding sites.
The DrrAB system is a multidrug transporter – To determine whether the DrrAB system can
actually transport other drugs in addition to Dox, two substrates (H 33342 and EtBr) commonly
used to establish the MDR phenotype (5,27), were tested in IOVs, as described under Methods.
In addition, five other fluorescent dyes or drugs (including Hoechst 34580, Hoechst 33258,
quinine, TMRM, and Rhodmine 123) were also tested. Of these substrates, H 33342 and EtBr
were successfully transported by the DrrAB system, as described below.
Hoechst is a cell-permeable dye, which is fluorescent only when bound to the cell
membrane and loses its fluorescence in aqueous environment. Thus a decrease in fluorescence is
expected when Hoechst is transported by the DrrAB system from the membrane to the inner
aqueous environment in the IOVs. Ethidium bromide, on the other hand, becomes fluorescent
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when bound to DNA inside the cells. Therefore, DrrAB-mediated efflux of EtBr was studied in
preloaded cells, as described under Methods. EtBr efflux under this condition is expected to
result in quenching of fluorescence. The data in Fig. 5 show that both H 33342 (Fig 5A.1) and
EtBr (Fig 5B.1) are transported efficiently by the DrrAB system. In the case of H 33342, the rate
of transport was seen to decrease after an initial linear phase of transport. This is likely due to
depletion of H 33342 in the membrane and due to passive rebinding of H 33342 to the membrane
from the aqueous phase, as shown earlier in the case of Pgp (27). To determine the kinetic
parameters for the transport of H 33342 and EtBr, efflux of each substrate was analyzed at a
wide range of concentrations. The initial rate of H 33342 transport in DrrAB-containing IOVs
was measured between 0.1 µM and 2.5 µM (Fig 5A.2). The efficiency of H 33342 transport was
calculated, as described earlier for Dox (Fig. 1C). The data were plotted using the MichaelisMenten equation by the Sigma Plot kinetics software and could be fitted to a hyperbola with an
R2 of 0.90, yielding an apparent Km of 0.78 µM and Vmax of 16000 (a.u.). To study kinetics of
EtBr transport, energy-depleted cells were loaded with different concentrations of EtBr (ranging
from 1 µM to 100 µM) for 1 hour, and efflux was initiated by addition of 20 mM glucose (Fig
5B.2). The data fitted to the hyperbola (Michaelis-Menten equation) with an R2 of 0.97, yielding
an apparent Km of 21µM and Vmax of 550 (a.u.). The data in Fig 5 show that both H 33342 and
EtBr are transported efficiently by the DrrAB system. A comparison of the Km and Vmax values
for transport of Dox, H 33342, and EtBr is shown in Fig 5, panel C. Five other fluorescent
substrates (Hoechst 34580, Hoechst 33258, quinine, tetramethylrhodamine(TMRM), and
Rhodmine 123) tested in this study were not found to be exported by the DrrAB system (data not
shown). In general, the transport data agreed with the inhibition data shown in Fig. 3, panel D.
Interestingly, of the three Hoechst dyes tested, only H 33342 was transported. Recent studies
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showed that a certain balance between the hydrophobic and hydrophilic forces in the structure of
the target substrate is essential for optimum efflux by Pgp (111). Since H 33342 is the most
amphiphilic of the three dyes, this may explain why DrrAB is able to preferentially transport H
33342 but not the other two dyes.
2.8

Discussion
Multidrug resistance is conferred by the action of specialized proteins in the cell

membrane that have the ability to carry out energy-dependent efflux of structurally and
functionally unrelated hydrophobic compounds. This phenomenon defies the concept of single
enzyme-single substrate (the lock and key model), which is applicable to most other enzymes.
Since the discovery of multidrug resistance in human cancer cells and bacteria (112-114), two
important questions have remained at the forefront of this field: 1) what is the basis of polyspecific drug recognition and transport by MDR proteins? 2) How and why does MDR evolve?
Extensive biochemical analysis of Pgp (87,89,90) as well as the availability of three-dimensional
structures of the drug-bound forms of Pgp, AcrB, BmrR and QacR (42,91,115,116) has
contributed significantly to understanding the molecular basis of poly-specific drug binding.
These studies indicate that the MDR proteins contain an extensive (and flexible) drug binding
pocket which can accommodate multiple drugs simultaneously via interactions with specific
(sometimes overlapping) aromatic and polar residues present in different parts of the pocket.
The 3-D structure of Pgp, in particular, also provides support for the hydrophobic vacuum
cleaner model, which was proposed early on by Gottesman and colleagues (4,17) to explain the
mechanism of multidrug transport. According to this model, Pgp substrates (which are primarily
cationic, lipid soluble, planar molecules) partition spontaneously into the membrane and are
picked up by Pgp directly from the membrane (instead of from the cytoplasm) and then removed
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by its ability to flip drugs from the inner to the outer leaflet. This model, which has now been
extended to many other MDR proteins (21), makes a clear distinction between the classical
solute transporters that remove molecules from an aqueous compartment and the MDR proteins
that are proposed to function as flippases (117). A clear relationship between the ability of drugs
to partition into the membrane and their binding and transport by Pgp has since been documented
(24,118,119). Additional evidence in support of this model comes from 1) the ability of most
MDR proteins studied to date to extrude the lipopilic dye H 33342 directly from the membrane
(7,27,32,120), thus making it an ideal molecule to establish the MDR phenotype and 2) the
ability of many MDR proteins to flip-flop lipids (121-124). Together, these observations led to
the idea that hydrophobic drugs and lipids may use a common pathway or flipping mechanism
for extrusion.
Despite significant progress in understanding the basis of poly-specific drug-binding, the
origin of multidrug resistance still remains an enigma. It is generally accepted that most of the
antibiotic and drug resistance genes found in clinical settings have their origins in the
environmental bacteria (87). Indeed many antibiotic producing organisms contain dedicated
export systems to protect themselves against their own antibiotics (125,126). Understanding
these systems could hold the key to unraveling the origin and evolution of multidrug specificity.
It is generally assumed that the dedicated systems found in producer organisms belong to the
category of single-drug transporters as opposed to multi-drug transporters (88), however their
substrate specificity has never been investigated in any significant detail thus providing the
impetus for this study.
We show for the first time that the DrrAB system functions as a typical multidrug
transporter that can carry out efflux of structurally unrelated substrates, including Dox, ethidium
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bromide and H 33342. Inhibition studies further demonstrate that the substrate range of the
DrrAB system includes many additional substrates, such as verapamil, vinblastine, and rifamicin,
among others. Thus the substrate specificity of DrrAB overlaps with most other known MDR
proteins, including Pgp (127-129). We found, however, that unlike Pgp, neither quinine nor
rhodamine 123 serve as substrates for export by the DrrAB system nor did they show inhibition
of Dox transport. Therefore, in spite of the broad substrate range of DrrAB, it appears that the
range of substrates recognized by Pgp may still be larger (130), implying that the ability to bind
some of these substrates may have evolved later in Pgp. Interestingly, the IC50 values varied
significantly among different drugs, indicating the different binding affinities of each substrate.
The highest IC50 was observed for colchicine, which is consistent with the data previously
reported for Pgp (118,131,132). This may be related with low hydrophobicity of colchicines
(133), therefore indicating that the ability to partition into the membrane may be an important
factor for transport by both Pgp and DrrAB.
Kinetic characterization of Dox, H 33342, and EtBr transport by the DrrAB system
revealed single-site transport kinetics. Further, the Km values of 0.38 µM and 0.78 µM for
transport of Dox and H33342, respectively, reflect high affinity of these substrates for the DrrAB
system and correspond well with the Km values seen earlier for Dox transport by Pgp (134) and
Hoechst transport by MsbA and LmrA (5). Interestingly, however, we found that the kinetic data
for Dox as well as H 33342 could also be fitted by the Hill equation (shown in Fig. 5C)
providing the nHill value of 1.7 for Dox (R2 = 0.93) and 2.0 for H 33342 (R2 = 0.95), which
suggests co-operative interaction between two or more drug binding sites in DrrAB. It is not
clear from these data, however, whether both H 33342 and Dox bind to the same sites in the
DrrAB system. Since ethidium transport by DrrAB exhibited only single-site transport kinetics
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(nHill=1.1; R2 = 0.98) (Fig. 5C), it possibly interacts with only one of the Dox/Hoechst binding
sites, or it may bind to a completely different site in DrrAB. The kinetic analyses shown in Fig.
4 provide evidence for competitive inhibition of Dox transport by H 33342 and rifampicin and
non-competitive inhibition by verapamil. Therefore, we conclude that both H33342 and
rifampicin bind to the same site(s) as Dox, whereas verapamil may bind to a different site in
DrrAB. Evidence for two or more non-identical drug binding sites has also been obtained
previously with MsbA (5,122), LmrA (6) and Pgp (5,34,135). In Pgp, the two sites were defined
as the H and R sites based on their preferential binding to Hoechst and Rhodamine, respectively
(136). Together, these data point towards the presence of two or more drug binding sites in the
DrrAB system. Gleaning from the knowledge previously gained from studies with Pgp and
AcrB, these different drug binding sites are likely part of the same binding pocket in DrrB.
However, in the absence of a crystal structure of the DrrAB transporter, this conclusion is only
tentative.
Even though the present study does not provide an answer to the origin of poly-specific
drug recognition, it does indeed show that a simple system like DrrAB (which may be closely
related to the ancestral system) already contains the ability to recognize and transport multiple
substrates. This leads us to conjecture that the ability to transport multiple drugs is an inherent
property of a certain class of proteins that followed a different evolutionary path than the
classical transporters. This work also opens new questions regarding the mechanism by which
the DrrAB system extrudes multiple hydrophobic substrates. The most important of these
questions is whether this system relies on a hydrophobic vacuum cleaner-like mechanism and if
it is capable of flippase action? Doxorubicin is produced inside S. peucetius cells, therefore
presumably the function of the DrrAB system is to remove it from the cytoplasmic compartment
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to the outside. Being amphipathic, however, Dox could conceivably partition into the cell
membrane and then be picked up by the DrrB protein directly from the membrane, as suggested
in an early model proposed for AcrB function (91). This strategy for its removal could also
provide protection to the cell from the toxic effects of free Dox inside the cell. The ability to
transport Hoechst no doubt indicates that the DrrB protein can indeed extract this fluorescent dye
directly from the membrane by a mechanism similar to the one used by Pgp and other proteins
(5,27,129). Future studies will therefore focus on an in-depth analysis of the mechanism of drug
extrusion by the DrrAB system.
This and previous studies on MDR proteins raise many other intriguing questions; for
example, is there evolutionary relatedness between MDR proteins and lipid flippases? What is
the real difference between the single-drug and multi-drug transporters? What makes certain
proteins specific for a substrate and some others multi-specific? What is the contribution of high
aromatic amino acid content of the TM helices of MDR proteins in conferring poly-specificity?
Since the transmembrane helices of Pgp and other MDR proteins, such as the bacterial BMR, are
highly enriched in aromatic amino acids (18% and 15.4% for Pgp and BMR, respectively) as
compared to the single-drug transporter TetA (9.4%), Pawagi et al. proposed that a greater
number of aromatic amino acids may correlate with a decrease in substrate specificity of a
transporter by providing additional binding sites for drugs containing aromatic rings in their
structure (137). Moreover, it was shown that mutagenesis of a single residue Ser941 to Phe in
TM11 of Pgp significantly altered its drug efflux profile (138). The recent 3-D structure
confirmed that the drug-binding pocket of Pgp is made up of mostly hydrophobic and aromatic
residues (42). Interestingly, we found that the aromatic amino acid content of predicted TM
helices of DrrB (84) is also relatively high (15%) which is close to the aromatic content of Pgp

62

(18%) and BMR (15.4%). Whether this plays a role in conferring multi-specificity in DrrB will
be determined in future studies by mutagenesis of specific aromatic and other residues in DrrB.

Table 3.1 Bacterial strains and plasmids

Name

Description
Reference
Bacterial Strains or Plasmid
supE44 supF58 hsdR514 galK2 galT22 metB1 trpR55
(96)
LE392 ΔuncIC
lacY1 Δ uncIC
Cloning vector, pACYC184 derivative, Cmr
(59)
pSU2718
drrAB in pSU2718, Cmr
(59)
pDX101
r
drrA in pSU2718, Cm
(59)
pDX102
drrB in pSU2718, Cmr
(59)
pDX103
44
44
drrAB in pSU2718 with mutation of Gly to Ala in
(104)
pDX101(G44A)
the Walker A domain of drrA
drrAB in pSU2718 with mutation of Gly44 to Ser44 in
(104)
pDX101(G44S)
the Walker A domain of drrA
drrAB in pSU2718 with mutation of Lys47 to Arg47 in
(104)
pDX101(K47R)
the Walker A domain of drrA
drrAB in pSU2718 with mutation of Ser141 to Arg141
(104)
pDX101(S141R)
in the Signature domain of drrA
drrAB in pSU2718 with mutation of Glu165 to Gln165
(104)
pDX101(E165Q)
in the Walker B domain of drrA
drrAB in pSU2718 with mutation of Gln197 to His197 This study
pDX101(Q197H)
in the switch motif of drrA
drrAB in pSU2718 with mutation of Tyr198 to Arg198 This study
pDX101(Y198R)
in the switch motif of drrA
drrAB in pSU2718 with mutation of Gln197 Tyr198 to This study
pDX101(Q197H/Y198R)
His197 Arg198 in the switch motif of drrA
pDX101(Q197H/Y198H) drrAB in pSU2718 with mutation of Gln197 Tyr198 to This study
His197His198 in the switch motif of drrA
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Figure 3.1 Characterization of the DrrAB-mediated Dox efflux under in vivo and in
vitro conditions.
These data were contributed by Wen Li and Madhu Sharma

FIGURE 3.1 Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro
conditions. (A) In vivo analysis of DrrAB-mediated Dox efflux using E. coli cells. E. coli
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were loaded with 10 µM Dox,
and the whole cell Dox efflux assay was performed, as described under Methods and in ref (61).
Dox efflux was measured fluorometrically (exi, 480 nm; emi, 590 nm) on an Alphascan-2
spectrofluorometer (Photon Technology International). Energy was provided in the form of 20
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mM glucose or 20 mM succinate at 100 seconds (marked with an arrow) and fluorescence was
monitored for an additional 400 seconds. 10 mM sodium fluoride (NaF) was added to the
samples, where indicated. A.1: Curve 1, pDx101(DrrAB)/glucose; Curve 2, pDx101
(DrrAB)/succinate; Curve 3, pDx101 (DrrAB)/glucose/NaF; Curve 4, pSU2718 (vector)/glucose;
Curve 5, pSU2718/succinate; Curve 6, pSU2718/glucose/NaF. A.2: Quantitative presentation
of the Dox efflux data shown in Fig 1A.1. The slope of the linear portion of each curve shown
in Fig 1A.1 was calculated. The slope of curve 1 was designated as 1.0. Relative slope of each
curve was then obtained by dividing the slope of the curve by the slope of curve 1. The average
data obtained from three independent experiments are shown in the histogram. (B) In vitro
analysis of DrrAB-mediated Dox efflux using inside-out membrane vesicles (IOVs). E. coli
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were grown to mid-log phase
and induced with 0.25 mM IPTG at 37 °C for 3 hr. The membrane fraction was prepared (49)
and Dox efflux in DrrAB-containing IOVs was performed, as described under Methods. B.1: In
vitro Dox efflux assay was carried out using 250 µg IOVs in the presence of 1 µM Dox, 0.1
mg/ml creatine kinase and 5 mM creatine phosphate in 3 ml PBS buffer, pH 7.5, as described
under Methods. Vector, Dox efflux in IOVs prepared from cells containing empty vector;
DrrAB, Dox efflux in IOVs prepared from cells containing pDX101 (DrrAB). B.2:
Quantitative presentation of Dox efflux in DrrAB-containing IOVs under various
conditions. In vitro Dox efflux assay was carried out in the presence or absence of 1 mM
ATP,1mM GTP, 1 mM Mg or 5 mM NADH, as described under Methods. The initial rate of
Dox efflux was determined from the linear slope of the fluorescence spectra between 100 s and
200 s. The slope of the efflux curve obtained by incubation of the DrrAB-containing IOVs with
ATP and Mg2+ (column 4) was designated as 1.0. The relative slope for each curve was then
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calculated by dividing the slope of the curve by the slope of sample 4. The average data
obtained from three independent experiments are shown in the histogram. (C) Kinetic analysis
of DrrAB-mediated Dox efflux in IOVs. In vitro Dox efflux was analyzed using 250 µg IOVs
in the presence of increasing concentrations of Dox (0.1 µM to 6.0 µM) and 1 mM ATP/Mg2+.
The initial linear rate of Dox efflux was determined for each curve. The data obtained from three
independent experiments were fitted to the Michaelis-Menten equation and plotted by
SigmaPlot-Kinetics software using the equation for Single Substrate Format. (D) Inhibition of
DrrAB-mediated Dox efflux by sodium o-vanadate. In vitro Dox efflux was measured using
250 µg IOVs in the presence 1 µM Dox, 1 mM ATP and 1 mM Mg2+ and increasing
concentrations of Vi (0 – 100 µM). The initial slope of the efflux curve obtained with 0 µM Vi
was designated as 1.0. The relative slope of each curve was determined, as described underpanel
A.2. The average data obtained from three independent experiments are shown in the histogram.
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Figure 3.2 Effect of point mutations in the nucleotide binding domain of DrrA on
DrrAB-mediated Dox efflux in IOVs.
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FIGURE 3.2 Effect of point mutations in the nucleotide binding domain of DrrA on
DrrAB-mediated Dox efflux in IOVs. (A) ClustalW alignment of the NBD of DrrA and its
prokaryotic or eukaryotic homologs. The conserved motifs present in the NBD are marked at
the top. A.1, alignment of the NBD of DrrA with ABC proteins (MalK, Sav1866, HlyB, TAP1,
TAP2, LmrC, LmrD and LmrA) from diverse families. A.2, alignment of the NBD of DrrA with
close prokaryotic homologs (belonging to the DRA family/DRR subfamily (50) identified by
NCBI BLAST. A.3, alignment of the NBD of DrrA with close eukaryotic homologs belonging to
the DRA family/ABCA subfamily (50). (B) Effect of point mutations in Walker A, Walker B,
or the Signature motif of DrrA on DrrAB-mediated Dox efflux in IOVs. E. coli
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), pDX102
(drrA only, in pSU2718), pDX103 (drrB only, in pSU2718) or pDX101 containing mutations of
Walker A (G44A, G44S, K47R), Signature motif (S141R), or the Walker B (E165Q) were
induced with IPTG, and the IOVs were prepared, as described under Methods. The initial rate of
Dox efflux was determined for each sample, and the relative slopes were calculated, as described
for Fig. 1. The average data obtained from three independent experiments are shown in the
histogram. (C) Effect of point mutations in the Switch motif of DrrA on DrrAB-mediated
Dox efflux in IOVs. E. coli LE392ΔuncIC cells containing either pSU2718 vector, pDX101
(drrAB in pSU2718), or pDX101 with mutations of the Walker B region (E165Q) or the Switch
motif (Q197H, Y198R, Q197H/Y198H, Q197H/Y198R) were induced with IPTG, and the IOVs
were prepared, as described under Methods. The initial rate of Dox efflux was determined for
each sample, and the relative slopes were calculated, as described for Fig. 1. The data presented
are averages of three independent experiments. Error bars represent standard deviation. (D)
Effect of point mutations in the Switch motif of DrrA on DrrAB-mediated ATPase activity
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in IOVs. IOV samples from Fig. 2(C) were subjected to the NADH-coupled ATPase activity
assay, as described under Methods. The relative ATPase activity of each sample was obtained
by dividing the activity of each sample by the activity of wild type. The data presented are
averages of two independent experiments. Error bars represent standard deviation. (E)
Summary of the ATPase activity and Dox efflux activity of wild type DrrAB and Switch
motif mutants.

Figure 3.3 Inhibition of DrrAB-mediated Dox efflux by known MDR substrates.
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FIGURE 3.3 Inhibition of DrrAB-mediated Dox efflux by known MDR substrates. Dox
efflux was measured using 250 µg IOVs in the presence 1 µM Dox and increasing
concentrations of the inhibitory substrate in 3ml PBS, pH 7.5. The initial linear rate (100 s - 200
s) of Dox efflux was determined after addition of 1mM ATP/Mg2+. The slope of the efflux curve
obtained at 0 concentration of inhibitor was designated as 1.0. The relative slope of each curve
was then determined. The average slopes resulting from three independent repeats were plotted
by Sigma Plot software using ‘scatter plot with error bars’, and IC50 values were determined. (A)
Kinetic analysis of the inhibitory effect of Hoechst 33342 on Dox efflux activity. The
experimental conditions were the same as described above. The assay was carried out in the
presence of increasing concentrations of H 33342 ranging from 0 – 1.6 µM. (B) Kinetic
analysis of the inhibitory effect of verapamil. The experimental conditions were the same as
for Fig. 3(A), except that the concentration of verapamil ranged from 0 µM to 100 µM. (C)
Kinetic analysis of the inhibitory effect of Rifampicin. The experimental conditions were the
same as for Fig. 3(A), except that the concentration of rifampicin ranged from 0 µM to 75 µM.
(D) A table showing summary of the IC50 values. Kinetic analysis of the inhibitory effect of
various drugs on DrrAB-mediated in vitro Dox efflux was determined, as described above for
panels 3A-C. The IC50 values were calculated as described under Methods.
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Figure 3.4 Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux
by Hoechst 33342, verapamil or rifampicin

FIGURE 3.4 Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux by
Hoechst 33342, verapamil or rifampicin. The kinetics of DrrAB-mediated Dox efflux was
determined in the presence of fixed concentrations of inhibitor, as shown in panels 4A-C. (A)
Competitive inhibition by H 33342. DrrAB-mediated Dox efflux was studied at four different
concentrations of Dox (0.25, 0.5, 0.75 and 1.0 µM) in the presence of a fixed concentration of
H33342. In total, four different concentrations of H 33342 (0, 0.2, 0.6, 0.8 µM) were studied.
The rate of Dox transport obtained with 1 µM Dox and 0 µM H 33342 was designated as 1.0.
The relative rates were then calculated for each efflux curve, and the data were plotted by
Lineweaver-Burk plot using Sigma Plot- Kinetics software in Single Substrate – Single Inhibitor
Kinetics Format. The error bars represent three separate experiments. The type of inhibition
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was determined based on the rank of both AICc and R2. (B) Non-competitive inhibition by
verapamil. The experiment was performed as described under panel (A). Four different
concentrations of verapamil (0, 3.5,7, 14 µM) were used. (C) Competitive inhibition by
rifampicin. The experiment was performed as described under panel (A). Four different
concentrations of rifampicin (0, 5, 10, 20 µM) were used. (D) Summary of the kinetics
constants obtained for inhibition of Dox efflux byH 33342, verapamil and rifampicin.

Figure 3.5 The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated
Hoechst 33342 efflux in IOVs.
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FIGURE 3.5 The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated
Hoechst 33342 efflux in IOVs. The E. coli inside-out membrane vesicles were prepared, as
described under Methods. 250 µg IOVs were mixed with 0.5 µMH 33342, 0.1 mg/ml creatine
kinase and 5 mM creatine phosphate in 3ml PBS buffer, pH 7.4. The fluorescence spectra were
recorded on an Alphascan-2-spectrofluorometer with excitation of 355 nm and emission of 457
nm. After 100 s, the detection was paused, and 1mM Mg2+ and 1mM ATP, pH 7.5 were added
into the reaction. The detection was continued for additional 250 s. Vector, IOVs prepared from
cells containing empty vector; DrrAB, IOVs prepared from cells expressing DrrAB. (A.2)
Kinetic analysis of DrrAB-mediated H 33342 efflux in IOVs. The experimental conditions
were the same as described under A.1 above. However, H 33342 efflux was analyzed at
concentrations ranging between 0.1 µM to 2.5 µM. The initial (between 100 s-200 s) linear rate
of H 33342 efflux was determined. The data obtained from three independent experiments were
fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single
Substrate Kinetics Format. (B.1) DrrAB-mediated ethidium bromide efflux in E. coli cells. E.
coli cells containing empty vector or DrrAB were loaded with 25 µM EtBr for 1 hr at 37 °C.
Energy was provided in the form of 20 mM glucose, and EtBr efflux was measured, as described
under Methods. (B.2) Kinetic analysis of DrrAB-mediated EtBr Efflux in E. coli cells. The
experimental conditions were the same as described under B.1 above. However, EtBr efflux was
analyzed at concentrations ranging between 1 µM to 100 µM. The steady-state linear rate of
EtBr efflux was determined. The data obtained from three independent experiments were fitted
by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single Substrate
Kinetics Format. (C) Summary of the kinetic parameters obtained by using MichaelisMenten or Hill equation for DrrAB-mediated Dox, H33342, and EtBr efflux.
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4

GENERAL DISCUSSION

The fast development of therapeutic agents has been compromised by the increasing
problems of multidrug resistance both in infectious microorganisms as well as in cancer cells.
Streptomyces peucetius, a soil microorganism that produces anti-cancer drugs Dox and Dnr, is
self-resistant to these drugs due to the expression of the DrrAB drug efflux system on the
membrane. Because of the limited knowledge of the mechanism as well as the evolution of
multidrug resistance, the prototype DrrAB system found in the producer organism can serve as
an excellent model to understand various aspects of the phenomenon of MDR.
In our current studies, we have demonstrated that DrrAB is a multidrug transporter. It
can efficiently transport Dox, Hoechst 33342 and ethidium bromide in whole cells as well as
membrane vesicles.

Dox transport activity could be inhibited by verapamil, rifampicin,

vinblastine and colchicine, suggesting that these drugs are also substrates of DrrAB. DrrAB
belongs to the ABC family of transporters and shares high similarities in sequence, structure and
function with P-gp. Our studies showed that DrrAB and P-gp share some of the substrates,
although Pgp can transport a much larger range of structurally unrelated compounds. Kinetics
studies of drug efflux by DrrAB indicated competitive inhibition of Dox transport by Hoechst
33342 and rifampicin but non-competitive inhibition by verapamil.

These studies raise

intriguing questions about whether DrrAB contains more than one drug binding site, how these
drugs interact with DrrB, and how does the conformation of DrrA and DrrB change during the
drug transport process? Further studies such as identification of the drug binding sites, analysis
of specific drug transport mechanism in purified and reconstituted proteoliposome, and the crosstalk between NBDs and TMDs during ATP binding, hydrolysis and drug efflux are required.
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The drug binding sites of P-gp have been under investigation for several decades. In
early 1994, Pawagi and Deber showed that the TMHs of P-gp are highly enriched in aromatic
amino acids (18%) as compared to the single-drug transporter TetA (9.4%) (137). Later, Loo
and Clark used biochemical approaches to identify the drug binding sites of P-gp. Their work
showed that the drug binding interfaces are located at TMHs 4, 6, 10, 11 and 12 (29,35,3739,139). Substitution of a single serine to phenylalanine in TM11 of P-gp significantly altered
its drug efflux profile, indicating the significant roles of residues in TMH11 in the recognition
and transport of their specific substrates (138). Not until recently, the crystal structure of P-gp
with higher resolution was presented by Chang’s group (42). In their description, P-gp with two
bundles of six TMHs forms a large internal cavity open to both the inner leaflet and the
cytoplasm. The drug binding pocket is made up of mostly hydrophobic and aromatic residues;
only 13 of the 73 residues in the internal cavity are polar or charged. The upper half of the
pocket contains mostly hydrophobic/aromatic residues while the lower half pocket mainly
consists of charged/polar residues. Interestingly, based on the topological structure and
modeling analysis of DrrB (84), the aromatic amino acid content of predicted TMHs of DrrB
(15%) is close to the aromatic content of P-gp (18%) and the bacterial MDR protein (15.4%)
(137). The hydrophobic and aromatic residues are mainly located in TMHs 1, 5, 6 and the Nterminal loop of the single monomer of DrrB. The N-terminal loop and TMH1 might be
particularly important since they directly connect the TMDs of DrrB to the catalytic domain of
DrrA (10). To determine whether these domains are involved in drug binding, single point
mutations can be introduced in the potential drug binding domains in DrrAB. Mutations in any
residues that are essential for drug binding will affect the transport of substrates (36,140,141).
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Another major question of DrrAB drug transport is the cross-talk between DrrA and
DrrB. The role of the conserved EAA motif found in the first intracellular loop of the TMD in
communication with the NBD has been studied in bacterial importers and exporters (142). In our
lab, we identified an EAA-like motif at the N-terminal cytoplasmic tail of DrrB (10). Sequence
alignment analysis showed that DrrB, LmrA, MDR1, CFTR, MsbA and BtuC share a conserved
EAA-like motif. Chemical cross-linking analysis indicated that DrrA cross-links with cysteines
introduced in both the N-terminal and C-terminal ends of DrrB. Thus, this EAA-like motif may
be involved in the interaction between DrrA and DrrB proteins. Later in our laboratory, a
CREEM motif (C-terminal Regulatory Glu (E)-rich Motif), located in the extreme C terminus of
DrrA, was found to interact with the EAA-like motif in the N-terminal cytoplasmic tail of DrrB
(10,61). Taken together, both the EAA-like motif at the N terminus of DrrB and the CREEM
motif at the C terminus of DrrA are significant for the interaction between DrrA and DrrB
protein as well as the biogenesis of the DrrAB complex (61).

However, how energy is

transduced between NBDs to TMDs and after the drug was transported still remains to be
understood (143).
In this work, I also studied the role of the FtsH protease in quality control and biogenesis
of the DrrAB complex in the membrane. FtsH was first identified by Ito and co-workers, who
suggested that FtsH may be involved in protein assembly into and through the membrane and in
determining the orientation of membrane proteins (73). Chaperone function was also proposed
for other ATP-dependent proteases, such as ClpAP/XP, YTA10/12 and Lon (144-147).
However, no direct evidence for the role of FtsH or any other protease in the functional assembly
of membrane proteins was obtained. In our studies, we provide the first direct evidence that
FtsH can perform both proteolytic and refolding functions in the assembly of the DrrAB
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complex. The most critical evidence for the refolding function of FtsH was obtained through the
sequential expression studies. We show that FtsH expressed after nonfunctional DrrA and DrrB
had accumulated in the membrane, was still able to restore the drug efflux function of the DrrAB
complex. Our studies also allow us to conclude that although the AAA domain of FtsH provides
recognition and specificity for binding of the substrate, both ATP hydrolysis and the proteolytic
functions of FtsH are used concurrently for the refolding of DrrAB and restoration of its efflux
function.
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